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Abstract 
 
Dialysis-related amyloidosis (DRA) is a frequent complication of end-stage renal 
disease that has been associated with the accumulation of β2-microglobulin (β2m).  
Excluding transplantation, existing kidney replacement technologies are believed to remove 
insufficient quantities of β2m for the prevention of DRA, as they are non-specific and based 
on size-exclusion.  A proposed DRA therapy is to use immunoadsorptive particles within an 
extracorporeal Vortex Flow Plasmapheretic Reactor (VFPR) to specifically remove β2m from 
blood.  The compartmental design of the VFPR allows for the use of small adsorbent 
particles (~100 µm) that possess inherent mass-transfer advantages over the larger ones 
(>400 µm) that are required for safe contact with whole blood for this application.  
Demonstrating the efficacy of this technology as a therapy for DRA would support its 
tailored application for treating other pathologies that are caused by circulating compounds 
such as sepsis, liver failure, autoimmune disease, drug overdoses, and genetic disorders. 
Whole anti-β2m antibodies (BBM.1) were immobilized onto agarose beads and used 
within a VFPR to remove donor baseline and defined quantities of recombinant β2m from 
whole human blood, in vitro.  A dynamic immunoadsorption model was developed for the 
VFPR that was based upon the independent characterization of the mass-transfer processes 
within the VFPR and the thermodynamics of the immunoadsorbent.  The experimentally-
observed and model-predicted dynamics of β2m clearance from the blood indicate that the 
process controlling the rate of β2m removal was the hemofiltration rate (50 mL-plasma/min), 
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which was on the order of the reported supply rate of β2m into the vasculature (70 mL-
plasma/min).  
Single-chain variable region (scFv) antibody fragments offer several potential 
advantages over whole antibodies due to their size and genetic definition, as well as their 
amenability for microbial expression and in vitro evolution.  Hence, a BBM.1 scFv was 
expressed by a yeast display vector and its affinity was quantified with a fluorescence-
activated cell sorter (KD = 0.008 ± 0.004 mg-β2m/L).  Soluble scFv was secreted by yeast and 
immobilized onto agarose beads (adsorption site density of 0.41 ± 0.01 mg-β2m/mL-settled-
gel).  These results support the feasibility of using the proposed therapy to treat and/or 
prevent DRA. 
 
Thesis Supervisor:  Robert Langer 
Title:  Germeshausen Professor of Chemical and Biomedical Engineering 
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Chapter 1:  Introduction 
1.1  MOTIVATION 
A frequent complication of end-stage renal disease (ESRD) is dialysis-related 
amyloidosis (DRA), a debilitating disorder associated with the long-term accumulation of β2-
microglobulin (β2m) [Gejyo et al., 1985; Drueke, 2000].  Symptoms are caused by the 
formation of amyloid deposits and include chronic pain, carpal tunnel syndrome, nerve 
compressions, and cystic bone lesions with associated fractures.  β2m, the primary 
constituent of DRA amyloid, is a highly conserved globular protein (11.8 kD) that is secreted 
by all nucleated cells and is specifically removed from the blood plasma by healthy kidneys.  
Presently, there are no widely available treatments to prevent this chronic and debilitating 
disease, short of a kidney transplant.  Conventional kidney function replacement technologies 
such as hemodialysis, hemodiafiltration, and peritoneal dialysis are believed to remove 
insufficient quantities of β2m, as they are non-specific and based on size-exclusion [Ameer, 
2001].  Even so, research has revealed a correlation between the removal of β2m from the 
circulation and a delay in the occurrence of symptoms [Miyata et al., 1998; Drueke, 2000; 
Lornoy et al., 2000].  In recent years, adsorbents that are based on hydrophobic adsorption 
and size-exclusion (Lixelle® and Betasorb®) have been developed for the extracorporeal 
removal of β2m [Furuyoshi et al., 1998; Davankov et al., 2000].  However, their specificity 
and/or affinity for β2m remains in question, complicating the evaluation of patient outcome 
due to their use [Tsuchida et al., 1998; Reiter et al., 2002; Tsuchida et al., 2002].   
Ideally, an adsorbent material for the extracorporeal removal of β2m should be highly 
specific, so as to prevent the significant loss of proteins and other molecules that are 
beneficial to the patient.  Furthermore, a highly specific β2m-adsorbent material could also 
serve as a valuable tool for research.  It could potentially be used to study the therapeutic 
efficacy of β2m clearance independent of the removal of other molecules that have also been 
implicated in the pathogenesis of DRA, such as inflammatory cytokines [Miyata et al., 1994; 
Matsuo et al., 2000; Niwa, 2001].  The optimal β2m-adsorbent should possess an affinity for 
β2m that is strong enough to bring the concentration to a level that is well below normal (1 
mg/mL [Floege and Ketteler, 2001]).  This high affinity would serve to increase the rate of 
β2m removal from the patient by maximizing the concentration gradient that drives the mass-
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transfer rate of β2m to the adsorption sites.  Along these lines, the adsorbent material should 
consist of small porous particles in order to minimize the time-scales of convective and 
diffusive mass-transport.   
Antibodies are a logical choice as the active species (or ligand) on which to base a 
β2m-adsorbent material, as they can be highly specific and possess a high affinity for their 
target molecules.  In the past, antibodies immobilized onto small porous beads have been 
used to clear β2m from human plasma [Mogi et al., 1989; Nakano et al., 1991; Vallar et al., 
1995; Shabunina et al., 2001].  However, this research did not address the challenge using of 
small (i.e. 100 µm) immunoadsorptive particles for the removal of β2m from whole blood in 
a clinically feasible system.  It is necessary to perform plasmapheresis (the separation of 
plasma from blood cells) before using small (< 400 µm) beads for the extracorporeal removal 
of β2m because unacceptably high levels of blood cell lysis occur when packed beds of this 
type are perfused with whole blood (direct hemoperfusion or DHP) under these conditions 
[Furuyoshi et al., 1998].  While packed beds of relatively large (> 400 µm) beads (Lixelle® 
and Betasorb® columns) have been safely used for this application [Furuyoshi et al., 1998; 
Davankov et al., 2000], they possess inherent mass-transfer limitations.  In fact, due to the 
low surface area to volume ratio of such large particles, the rate of toxin removal is directly 
proportional to the volume of adsorbent.  Hence, increasing the volume of adsorbent used for 
DHP can increase the rate of blood detoxification, but this comes at the expense of additional 
blood hold-up (a biocompatibility issue).  This is why the volumes of DHP columns used to 
date (Lixelle® and Betasorb®) for the extracorporeal removal of β2m have been kept below 
350 mL [Furuyoshi et al., 1998; Ronco et al., 2001]. 
As immunoadsorption ligands, single-chain variable region antibody fragments (scFv, 
Figure 1.1) offer several potential advantages over whole polyclonal or monoclonal 
antibodies.  The transfer of antibody genes to a defined expression vector provides the 
opportunity to eliminate the production of unwanted immunoglobulins.  ScFv fragments are 
also smaller in size, which should theoretically allow for higher effective β2m adsorption site 
densities (steric argument).  This would reduce the volume of adsorbent required for 
therapeutic efficacy, thereby minimizing the retention of blood components during operation.  
Additionally, the properties (affinity, stability, expression yield) of scFv fragments can be 
engineered through in vitro evolution in a yeast display format [Boder and Wittrup, 1997; 
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Boder and Wittrup, 1998; Boder and Wittrup, 2000].  The fact that scFv fragments can be 
produced through microbial expression vectors provides greater flexibility for the 
optimization of the production process economics [Datar et al., 1993].  Furthermore, very 
high yields (3.1 g-scFv/L-culture) of properly folded scFv fragments have been expressed in 
and purified from the cytoplasm of E. coli [Martineau et al., 1998]. 
The Vortex Flow Plasmapheretic Reactor (VFPR, refer to Figure 1.2 and Section 1.3) 
is a multi-compartment extracorporeal device that was originally developed to carry out the 
safe and efficient enzymatic neutralization of heparin in whole blood [Ameer, Barabino et 
al., 1999; Ameer, Raghavan et al., 1999].  The VFPR is the first device designed to use 
Taylor vortices and a fluidized bed of particles to conduct a heterogeneous reaction or 
adsorption process on whole blood.  A major advantage of fluidized beds over packed beds is 
that they exhibit lower pressure drops (when all other specifications are held constant) [Kunii 
and Levenspiel, 1977].  The fluidized bed of the VFPR also possesses an unusually high 
aspect ratio (length of the mesh divided by the radial distance between the membrane and 
mesh), which also contributes to its low-pressure drop (generally less than 20 mmHg).  Most 
importantly, however, the compartmental design of the VFPR allows for the use of relatively 
small (approximately 100 µm) active particles that possess inherent mass-transfer advantages 
over larger ones.  The relatively high surface area to volume ratio of these smaller particles 
could potentially allow for a significant reduction in the volume of the adsorbent required for 
the effective extracorporeal removal of β2m, which would represent an improvement in 
biocompatibility. 
The research presented herein investigates the feasibility of using the VFPR design 
for the immunoadsorptive extracorporeal removal of β2m through experiments with whole 
human blood, in vitro.  Initially, immobilized whole monoclonal antibodies and a device 
prototype are investigated as a model system.  A mathematical model that describes the 
dynamic behavior of the immunoadsorptive VFPR is presented that is intended to serve as a 
design tool for future device prototypes, experiments, and potential clinical trials.  Finally, a 
new type of immunoadsorbent for the extracorporeal removal of β2m is developed that is 
based upon scFv antibody fragments.  The goal of this research is to lay a foundation for a 
new extracorporeal β2m-removal technology that is more specific, biocompatible, and 
effective than existing methods.   Demonstrating the efficacy of this technology as a therapy 
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for DRA would support its tailored application for treating other pathologies that are caused 
by circulating compounds such as sepsis, liver failure, autoimmune disease, drug overdoses, 
and genetic disorders. 
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1.2  SPECIFIC AIMS 
This thesis investigates feasibility of using the VFPR design with immobilized 
antibodies for the extracorporeal removal of β2m as a potential therapy for DRA.  More 
specifically, this thesis aims to: 
1. Evaluate the biocompatibility and efficacy of an immunoadsorptive VFPR for this 
application through experimentation with recombinant human β2m, monoclonal 
antibodies, and a reservoir of whole human blood, in vitro.  Here, biocompatibility 
will be assessed in terms of the effect that the immunoadsorptive device has on blood 
components (complete cell count, total protein, and plasma free hemoglobin).  The 
efficacy of the device is defined as its ability to bring the β2m concentration down to 
a level that is below the normal range of healthy individuals (1.0-3.0 mg/L [Floege 
and Ketteler, 2001]) at a clinically relevant flowrate (on the order of 70 mL-
plasma/min, the approximate flowrate of extravascular β2m into the circulation 
[Floege et al., 1991]).   
2. Develop a mathematical model for the immunoadsorptive VFPR that is based upon 
the independent characterization of the mass-transfer processes within the device and 
the thermodynamic behavior of a model immunoadsorbent.   
3. Create and characterize a novel β2m-adsorbent material that is based upon high-
affinity scFv antibody fragments and possesses a mass ratio of adsorbed β2m to 
immobilized antibody that is at or above the theoretical limit for bivalent whole 
antibodies (0.16 mg-β2m/mg-antibody).  For this application, a high-affinity scFv 
fragment is defined as one that has an equilibrium dissociation constant that is well 
below the lower limit of β2m concentrations found in healthy individuals (KD << 1 
mg-β2m/L ≈ 100 nM).  Creating an immunoadsorbent with a high mass ratio of 
adsorbed β2m to immobilized antibody (under saturating conditions) would support 
the future development an immunoadsorbent with the highest β2m adsorption site 
density reported to date (> 0.9 mg-β2m/mL-settled-gel [Vallar et al., 1995]). 
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1.3  THE VORTEX FLOW PLASMAPHERETIC REACTOR (VFPR)* 
 A VFPR is constructed by counter-boring two concentric chambers within the outer 
cylinder wall of a Taylor-Couette vortex flow device (Figure 1.2).  The collection chamber is 
sealed with a polyester mesh filter (15 µm opening) to keep the fluidized bed of particles 
within the active plasma chamber.  These particles are typically gel beads that are 
approximately 100 µm in diameter, are highly porous, and have the active species 
immobilized onto them (i.e. an antibody or enzyme).  The active plasma compartment is 
sealed with a 1 µm pore-size, track-etched polyester membrane to prevent contact between 
blood cells and the gel beads.  Compartmentalization in this novel Taylor-Couette flow 
device eliminates red cell lysis due to particle fluidization and prevents white cell and platelet 
activation due to contact with the active gel beads [Ameer, Harmon et al., 1999].   
During operation, whole blood is pumped into the inlet port (typically 200-400 
mL/min) and channeled through the innermost annular, or blood, compartment.  A 
dedicated peristaltic pump (plasma pump) controls the plasma flowrate through the 
microporous membrane, the active plasma compartment, and the plasma collection chamber 
(typically 50-75 mL/min).  The rotation of the solid inner cylinder (usually at about 1.2x103 
rpm) is achieved via magnetic coupling and serves to create the Taylor vortices [Donnelly, 
1991] in the blood compartment.  These flow instabilities induce undulations throughout the 
unsupported microporous membrane, fluidizing the gel beads in the active plasma 
compartment.  The cleansed plasma exits the active plasma compartment via the collection 
chamber, which retains the gel beads.  The cleansed plasma is returned to the top of the 
device where it mixes with bypassed cells and plasma prior to exiting the VFPR via the blood 
outlet port.  These mechanisms enable the VFPR to perform high-flux plasmapheresis in 
series with a fluidized bed reaction or adsorption process.  The More detailed descriptions of 
specific device prototypes are provided Chapters 2 and 3 of this document and have been 
published elsewhere [Ameer, Barabino et al., 1999; Ameer, Raghavan et al., 1999]. 
 
 
                                                 
* This section has appeared in a research article originally published in the AIChE Journal [Grovender et al., 
2002].  It has been reproduced with permission of the American Institute of Chemical Engineers.  Copyright © 
2002 AIChE.  All rights reserved. 
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Figure 1.1 Structural comparison of whole antibodies and single-chain variable 
region antibody fragments (scFv).  Whole antibodies are approximately 150 kD, while 
scFv fragments are generally 25-30 kD.  The scFv fragment shown is assembled in a VH-
linker-VL configuration. 
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* This figure has been previously published in Kidney International [Ameer et al., 2001].  It has been used with 
permission from Blackwell Publishing.  Copyright © 2001 Blackwell Publishing.  All rights reserved. 
Figure 1.2 The Vortex Flow Plasmapheretic Reactor (VFPR).*  The whole blood path 
is shown in red, while the regions accessible only to plasma are shown in gold.  The 
Taylor vortices in the blood compartment reduce the cell polarization layer formed at the 
surface of the membrane (allowing for higher blood filtration rates) and induce periodic 
undulations in the unsupported microporous membrane.  These membrane undulations 
drive the mixing and fluidization of the active plasma compartment.   
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Chapter 2:  In Vitro Removal of β2-Microglobulin from 
Human Blood with an Immunoadsorptive VFPR* 
2.1  INTRODUCTION 
High plasma levels of β2-microglobulin (β2m) have been implicated in the formation 
of the severely destructive and potentially fatal amyloid deposits that are characteristic of 
dialysis-related amyloidosis (DRA) [Gejyo et al., 1985; Drueke, 2000]. Conventional renal 
replacement technologies remove insufficient quantities of β2m to normalize plasma levels 
[Ameer, 2001].  This limitation arises due to non-specific adsorptive qualities and reliance on 
size exclusion, which can also remove other middle molecular weight proteins.  These non-
specific approaches also make it difficult to evaluate the role and contribution of middle 
molecular weight molecules to the pathology of DRA and other morbidities of end stage 
renal disease.  A high affinity and biologically specific approach could target a protein, 
prevent significant loss of other important molecules, and improve the apparent adsorption 
rate within an extracorporeal device.  This chapter describes the use of agarose-immobilized 
murine anti-human β2m monoclonal antibodies in a Vortex Flow Plasmapheretic Reactor 
(VFPR) to remove donor baseline and controlled amounts of human β2m from human blood 
in vitro. 
 
2.2  METHODS 
2.2.1  Assays 
 Serum and plasma β2m concentrations were assayed with the β2-micro RIA 
(radioimmunoassay) kit available from Pharmacia-Upjohn (MI), while the buffer β2m 
concentrations were determined by using an extinction coefficient of 20,065 M-1 cm-1 at 280 
nm.  This value was derived from the published amino acid sequence of human β2m [Suggs 
et al., 1981] and the equation reported by Pace and co-workers [Pace et al., 1995].  Bradford 
protein assays were performed according to the dye manufacturers instructions (Bio-Rad, 
CA), using a bovine gamma globulin standard (Pierce, IL).  Plasma free hemoglobin assays 
were performed according to the instructions of a kit purchased from Sigma Chemical (MO).   
                                                 
* This chapter is a revised version of a research article previously published in Kidney International [Ameer et 
al., 2001].  It has been used with permission from Blackwell Publishing.  Copyright © 2001 Blackwell 
Publishing.  All rights reserved. 
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Complete blood counts and total protein assays were performed at the MIT Medical 
Laboratory. 
 
2.2.2  Protein Immobilization 
 BBM.1 monoclonal antibody (hybridoma purchased as ATCC HB-28) [Brodsky et 
al., 1979; Parham et al., 1983] and bovine serum albumin (BSA) were each immobilized 
onto 48 mL settled-volumes of Sepharose CL-4B agarose gel beads (Amersham-Pharmacia, 
Sweden) using a modified version of a method previously described [Cuatrecasas et al., 
1968]. 
 The gel beads were rinsed with 1 L of ultrapurified water, and then combined with 50 
mL of ultrapurified water and 100 mL of 2 M sodium carbonate.  After being chilled on ice, 
the agarose gel suspension was activated for 5 minutes with 20% w/v cyanogen bromide 
(each gram pre-dissolved in 1.5 mL acetonitrile).  The activated gel was rinsed sequentially 
with 1 L of each of the following ice-chilled fluids:  ultrapurified water, 1 mM hydrochloric 
acid, and bicarbonate buffer (0.5 M sodium chloride, 0.1 sodium bicarbonate, pH 8.3).  The 
fluid in the gel void volume was removed and the activated agarose was combined with the 
protein to be immobilized (167 mg of BBM.1 via Bradford dye assay and 174 mg BSA by 
dry weight) in 82 mL of phosphate buffered saline, pH 7.4 (PBS).  The protein was allowed 
to bind to the activated agarose suspension for 40 hours at 4OC with gentle mixing.  The 
buffer was removed from the agarose gel and assayed for its residual protein concentration 
(Bradford assay for BBM.1 and change in absorbance at 280 nm for BSA).  The activated gel 
was quenched by mixing it with a lysine buffer (0.2 M lysine, 0.5 M sodium chloride, 0.1 M 
sodium bicarbonate, pH 8.3) for one hour at 4OC.  The gel was rinsed quickly with 500 mL 
PBS and rinsed overnight with 200 mL PBS at 4OC.  The following day, the overnight rinse 
was replaced with fresh PBS.  A sample was incubated for one hour at 37 OC to check the 
thermal stability of the immobilized protein (Bradford assay).  Coomassie stained SDS-
PAGE was used to check for protein in the lysine quenching buffer and PBS rinses. 
 
2.2.3  Recombinant β2m Preparation 
 The β2m E. coli expression vector [Garboczi et al., 1992] was a generous gift from 
the Wiley Laboratory (Cambridge, MA) and the recombinant protein was produced in a 
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fashion similar to those previously described [Buchner and Rudolph, 1991; Fan et al., 1996].  
Each liter of Luria-Bertani medium (fortified with 0.4% w/v glucose and 0.100 mg/mL 
ampicillin) was inoculated with frozen stock, incubated at 37OC, and induced with 0.5 mM 
isopropyl β-D-thiogaloctopyranoside during the log growth phase.  The bacteria was 
centrifuged at 5k x g for 20 minutes and resuspended in 50 mM Tris-HCl, 25% w/v sucrose, 
1 mM sodium ethylenediaminetetraacetic acid (EDTA), 10 mM dithiothreitol (DTT), pH 8.0.  
Cell lysis and DNA degradation were effected through the addition of 1 mg/mL lysozyme, 
0.1 mg/mL DNase I (Sigma DN-25), 5 mM magnesium chloride, 1% Triton X-100, 1% 
sodium deoxycholate, 10 mM DTT, and 70 mM sodium chloride.  The insoluble protein was 
rinsed several times with 50 mM Tris-HCl, 100 mM sodium chloride, 1 mM EDTA, 0.5% 
Triton X-100, 1 mM DTT, pH 8.0 and one final time with 50 mM Tris-HCl, 1mM EDTA, pH 
8.0.  The washed inclusion body protein was solubilized in 8 M urea, 25 mM 2-[N-
morpholino]ethanesulfonic acid (MES), 10 mM EDTA, 0.1 mM DTT, pH 6.0 and 
ultracentrifuged for 30 minutes at 25OC and 186,000 x g.  The denatured protein was refolded 
through dilution into 100 mM Tris-HCl, 400 mM L-arginine-HCl, 2 mM EDTA, 0.5 mM 
oxidized glutathione, 5 mM reduced glutathione, pH 8.0.  The refolded β2m was purified via 
size-exclusion chromatography using prep-grade Superose® 12 resin (Amersham-
Pharmacia), eluted with 20 mM Tris-HCl, 150 mM sodium chloride, pH 8.0.  In order to 
remove residual refolding buffer, the β2m was dialyzed against the elution buffer with a 6-8 
kD membrane (Spectrum Laboratories, CA). 
 
2.2.4  Capacity of the Immunoadsorptive Media  
 Porcine serum, loaded with three different saturating concentrations of rβ2m, was 
used to quantify the capacity of the immunoadsorptive media.  Briefly, 10 mL of 50% 
gel/PBS suspension, 30 mL of 5 micron-filtered Porcine serum (GIBCO BRL, MD), and 
either 0.23, 0.31, or 0.40 mg of rβ2m (stock: 0.94 ± 0.02 mg/mL in elution buffer) were 
combined in 50 mL polypropylene tubes (Corning, NY).  The tubes were equilibrated under 
well-mixed conditions for at least 1 hour at 37OC.  The rβ2m-adsorptive capacity of the 
agarose-immobilized monoclonal antibody was calculated using Equation 2.1, where ρ′s is 
the adsorption site density on a settled bed volume basis (mg-rβ2m/L-settled-gel), Vtotal is the 
total volume of the system (mL), Vgel is the settled-volume of gel (mL), C0 is the initial 
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diluted concentration of rβ2m in the system (mg/L), and Ceq is the equilibrium concentration 
of desorbed rβ2m (mg/L). 
  ( )0totals eq
gel
V C C
V
ρ′ = −  [2.1] 
 
2.2.5  Clearance of β2m from Whole Blood by a VFPR in a Closed-Loop Circuit 
 The MIT Committee on the Use of Humans as Experimental Subjects approved all 
experiments with human blood.  Healthy, volunteer blood donors read and signed informed 
consent forms.   The staff at the Children’s Hospital Blood Donor Center (Boston, MA) 
performed the phlebotomies.  Each donation (450 mL nominal volume) was used the same 
day it was received and had 63 mL of citrate phosphate dextrose adenine solution added as an 
anti-coagulant (Baxter, IL).  The VFPR and circuit tubing were primed with 0.9% w/v 
sodium chloride (USP grade, Abbott Laboratories, IL) and the agarose gel was injected into 
the adsorptive compartment.  The blood bag was placed on a shaker and connected to the 
VFPR in a closed-loop circuit (Figure 2.1).  Before the plasma pump and VFPR cylinder 
were turned on, the main circuit pump was run for 5 minutes to mix the blood with the saline 
outside of the plasma chambers and plasma line.  During the first 60 minutes of a two-hour 
hemoperfusion, the native donor β2m was cleared from the circuit by running the plasma 
pump and the inner VFPR cylinder.  Samples were taken before and after this period, and the 
adsorptive chamber was flushed with 0.9% w/v sodium chloride (BBM.1 gel only). 
 The immunoadsorptive media (but not the BSA gel) was regenerated with 1.5 L of 
0.3 M glycine-HCl, pH 2.8.  The regenerated BBM.1 gel was rinsed with 1.5 L of PBS and 
re-injected into the adsorptive chamber of the VFPR.  Recombinant human β2m (1.5 mg in 
elution buffer) was injected into the circuit, allowed to mix with the blood for 5 minutes, and 
samples were taken.  The recombinant β2m was cleared from the circuit by turning on the 
plasma pump and VFPR cylinder.  Samples were taken over a period of 60 minutes and the 
media was regenerated as before (both BBM.1 and BSA).  The samples collected were 
assayed for their total protein, plasma free hemoglobin, complete blood count, and β2m 
concentration.  System efficacy was quantified by calculating the conversion of β2m 
adsorption, Xadsorption, as shown by Equation 2.2 (dimensionless).  Here M initial and Mfinal are 
the initial and final masses (mg) of desorbed β2m in the system, respectively. 
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2.2.6  Statistical Analysis 
 Observed variables are reported as the mean ± SEM (standard error of the mean).  All 
experiments were performed in triplicate (N=3), unless otherwise noted.  Analysis of 
variance (ANOVA) was used to determine the significance of the differences among three or 
more means, while the students two-sample t-test was used to compare pairs of means.  The 
criterion for significance was a two-tailed p-value of 0.05. 
 
2.3  RESULTS  
2.3.1  Protein Immobilization 
 Most of the BBM.1 (92%) and the BSA (97%) bound to the activated agarose gel, 
yielding immobilization densities of 3.0 and 3.5 mg/mL-settled-gel, respectively.  The lysine 
quenching buffer and the PBS rinses did not show significant amounts of BBM.1 on SDS-
PAGE as compared to equal volume samples of BBM.1 in PBS from before and after 
activated substrate contact.  Protein leaching, after 1 hour of 37OC incubation, in the BBM.1 
and BSA 1 samples was found to be only 2.9 ± 0.7 and 0.5 ± 0.2 mg/L-PBS, respectively.  
 
2.3.2  Capacity of the Immunoadsorptive Media 
 Table 2.1 shows the results from the adsorption capacity measurements.  The rβ2m 
binding capacity of the immunoadsorptive media, ρ′s, was calculated to be 30 ± 2 mg-rβ2m 
/L-settled-gel.  Assuming bivalent BBM.1-β2m binding, this value corresponds to a BBM.1 
efficiency of 6%.  There was no apparent effect of the 0.3 M glycine stripping buffer on the 
binding capacity. 
Initial Concentration 
C0 [mg/L, N=4] 
Final Concentration 
Ceq [mg/L] 
Binding Site Density 
ρ′s [mg-β2m/L-settled-gel] 
5.8 ± 0.1 2.1 ± 0.0 30. ± 0. 
7.7 ± 0.2 3.8 ± 0.2 32. ± 1. 
10. ± 0. 6.4 ± 0.3 29. ± 2. 
Table 2.1 Capacity of the Immunoadsorptive Media 
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2.3.3  Clearance of β2m from Human Blood with an Immunoadsorptive VFPR 
 The average total volume, native β2m concentration, and hematocrit of the 
anticoagulated human blood was 529 ± 6 mL, 1.3 ± 0.1 mg/L, and 0.38 ± 0.01, respectively 
(N=7).  The final native β2m concentration of the BSA circuit was 0.5 ± 0.0 mg/L, while that 
of the BBM.1 circuit was below detectable limits.  Table 2.2 presents the observed native and 
recombinant β2m adsorption conversions for the BBM.1 antibody and BSA control protein 
matrices.  The dynamics of rβ2m removal by the VFPR, loaded with BBM.1 gel, are 
illustrated by Figure 2.2.  The relatively low plasma line concentration (< 0.4 mg/L) indicates 
that the apparent β2m adsorption rate within the plasma chamber was not limiting.  
Furthermore, the time-scale of β2m clearance from the blood bag was in agreement with that 
obtained by dividing the total blood path volume (445 mL) by the plasma flow rate (50 
mL/min).  The initial and final recombinant β2m concentrations in the BBM.1 circuit were 
3.2 ± 0.2 and 0.2 ± 0.1 mg/L, respectively.  This observed initial value was in agreement with 
the value (3.4 mg/L) predicted by dividing the mass of injected rβ2m (1.5 mg) by the cell-free 
volume of the blood bag, circuit tubing, and VFPR blood chamber (445 mL).  The mass of 
rβ2m adsorbed by the BBM.1 was 28 ± 2 mg/L-gel (settled volume), which was not 
significantly different from the value of ρ′s measured a priori. 
  Native   Recombinant  
 Minitial 
[mg] 
Mfinal 
[mg] Xadsorption 
Minitial 
[mg] 
Mfinal 
[mg] Xadsorption 
BBM.1 [g] (N=4) 0.48±0.07 * 100%±6% 1.43±0.08 0.10±0.02 92%±2% 
BSA [g] (N=3) 0.37±0.04 0.26±0.01 29%±6% 1.80±0.05 1.89±0.11 * 
Significance p>0.05 p<0.002 p<0.0005 p < 0.02   
 
 Table 2.3 and Table 2.4 report the effects of the VFPR circuit on cellular blood 
elements and total protein, respectively.  The donor bag plasma free hemoglobin level (HbP) 
                                                 
* Below detectable limits.  
 Values were not compared due to the significant difference in the initial conditions. 
Table 2.2 Clearance of β2m from Human Blood by the VFPR, In Vitro. 
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was 4.3 ± 1.1 mg/dL, while HbP at the end of native β2m removal (1 hour) was 8.9 ± 2.2 
g/dL.  This increase corresponded to 0.33 mg/dL per circuit pass.  A HbP of 0.6 mg/dL per 
pass through a hemodialyzer is generally considered acceptable [Ameer, Barabino et al., 
1999]. 
  Native  Recombinant 
 Diluted Bag* Initial Final Initial Final 
Erythorcyte [M/µL] 3.39±0.08 3.23±0.20 3.26±0.08 3.18±0.11 3.51±0.15 
Leukocyte [k/µL] 4.2±0.5 4.2±0.5 3.9±0.5 4.0±0.5 4.3±0.5 
Platelet [k/µL] 164±13 175±15 162±13 161±18 172±20 
 
  Native  Recombinant 
 Bag Initial Final Initial Final 
BBM.1 (N=4) 19.3±0.4 18.1±0.5 19.7±1.4 14.8±0.4 15.8±0.3 
BSA (N=3)§ 19.1±0.5 17.7±0.4 18.5±0.54 ** 19.7±0.6 
Significance p>0.8 p>0.5 p>0.5 N.A. p<0.005 
 
                                                 
* Values were not compared due to the significant difference in the initial conditions. Concentrations 
determined by multiplying the donor blood bag measurement by the dilution factor resulting from the saline 
priming volume. 
 No significant differences were found among the mean observed values for each count type over the two hour 
period (ANOVA, p>0.4).  
 No significant differences were found among the mean observed values during the native phase (ANOVA, 
p>0.4).  A significant decrease was found between the native and recombinant phases (ANOVA, p<0.001), 
which was due to the flushing of the adsorptive compartment and the regeneration of the media. 
§ No significant differences were found among the mean observed values (ANOVA, p>0.1). 
** This sample was equivalent to the "Final Native" sample because the BSA gel was not regenerated. 
 Two-sample t-test. 
Table 2.3 Complete Blood Count Data for the BBM.1 VFPR Experiments (N=4). 
Table 2.4 Total Protein Data for the VFPR BBM.1 Experiments and BSA Controls. 
 38 
2.4  DISCUSSION 
 Although the clinical pathology of DRA is not fully understood, it has been shown 
that removal of β2m can apparently delay the onset of the disease and improve symptoms 
[Furuyoshi et al., 1998; Drueke, 2000; Lornoy et al., 2000].  For the first time, we have 
shown the feasibility of removing β2m from whole blood within a single device via 
immunoadsorption.  As a first step, agarose-immobilized murine anti-human β2m 
monoclonal antibodies (BBM.1) were used in a Vortex Flow Plasmapheretic Reactor (VFPR) 
to remove both native and recombinant human β2m from human blood, in vitro.  The 
characteristics and advantages of the VFPR have been previously shown for the enzymatic 
neutralization of heparin, to potentially make heparin anticoagulation during open-heart 
surgery and dialysis safer [Bernstein et al., 1987; Leaver et al., 1992; Ameer, Barabino et al., 
1999].  Porous agarose gel beads were suspended within the adsorptive/reactive compartment 
and did not come into contact with the blood cells, thereby minimizing hemolysis.  The 
agarose gel beads used in this study were hydrophilic and did not have any significant net 
surface charge, which could result in ion exchange phenomena.  Furthermore, the common 
use of agarose gel beads in size exclusion chromatography also reflects its low protein-
binding characteristic.  Our results demonstrated that a VFPR is able to clear low 
concentrations of β2m from whole blood at a clinically relevant flow rate, without any 
deleterious effects on the cellular blood components, total protein, or plasma free 
hemoglobin.  Other factors, such as complement activation could potentially be an issue with 
agarose gel beads.  However, the immobilization chemistry and support used in the study was 
a model system to establish feasibility. The ability of the VFPR to perform adsorption, 
without a separate plasma filter, should potentially render the device convenient for use 
during dialysis.  Furthermore, the relatively low whole blood priming volume of 50 mL 
should minimize hemodilution.   
Our approach offers several potential advantages.  The VFPR design overcomes the 
hemolysis and mass-transfer limitations associated with fluidized and packed columns when 
they are used for direct hemoperfusion [Ameer, Harmon et al., 1999].  The high affinity of 
the antibodies could potentially reduce patient β2m concentrations below those obtainable 
with a low-affinity, hydrophobic adsorbent.  The larger β2m-concentration difference 
between the plasma and the adsorptive surface should result in an apparent increased rate of 
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adsorption.  The high specificity of the antibodies should avoid the indiscriminate loss of 
desirable molecules.  In addition, immunoadsorption could potentially be used in clinical 
trials as a diagnostic tool to help determine whether or not β2m clearance is the underlying 
mechanism responsible for the therapeutic response of non-specific treatments.  Some 
investigators have shown that a hydrophobic adsorbent, thought to be selective for β2m, 
removed various cytokines [Tsuchida et al., 1998]. Therefore, defined immunoadsorbents 
could be targeted towards these molecules to help understand their role in the pathogenesis of 
DRA or other morbidities associated with ESRD. 
It is very difficult, and at times not practical, to reproduce in vitro all of the 
parameters that are characteristic of an in vivo or ex vivo situation.  Pathologic β2m levels and 
larger β2m distribution volumes were not tested due to the limited available quantities of the 
BBM.1 monoclonal antibody.  However, the dynamics of β2m removal from blood with the 
VFPR using the immobilized BBM.1 antibody as a model system could be evaluated.  The 
lower than expected immobilization yield of BBM.1 using the CNBr activated agarose beads 
was also observed with agarose immobilized protein A, which specifically binds the Fc 
region of an IgG antibody. This phenomenon could potentially be attributed to the expression 
of an additional immunoglobulin (impurity) in the hybridoma culture, or simply an inherent 
inability of immobilized BBM.1 to retain its binding activity.  Even though our initial β2m 
concentrations were relatively low, the adsorption kinetics of our system should not be 
negatively affected by higher initial β2m concentrations.  Provided a high-capacity 
immunoadsorbent media is used, β2m concentrations that are characteristic of ESRD should 
be cleared.  Vallar and co-workers have reported high immobilization efficiencies (67%, ρ′s 
= 0.9 mg-β2m/mL-settled-gel) of other Sepharose® CL-4B-immobilized anti-human β2m 
monoclonal antibodies [Vallar et al., 1995].  A VFPR containing an immunoadsorbent media 
of 0.9 mg-β2m/mL-settled-gel should remove clinically relevant quantities of β2m within the 
allotted treatment time.  A VFPR containing 300 mL of gel is potentially capable of 
removing 270 mg of β2m.  Depending on the initial plasma β2m levels, session duration, and 
the type of dialysis membrane used, up to 250 mg β2m /session can be removed via filtration 
and non-specific adsorption (about 100 mg/4-hr-session on average) [van Ypersele de 
Strihou et al., 1994].  However, the key difference is the high affinity and specificity of 
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immunoadsorption.  High affinity is important because it helps maintain a high apparent 
adsorption rate within the VFPR.   
To date, the emphases of attention to remove β2m from blood under clinically 
relevant conditions have been filtration and hydrophobic interactions between the β2m and 
the adsorptive media [Furuyoshi et al., 1998; Kay, 1999; Davankov et al., 2000; Drueke, 
2000].  However, the specificity and affinity of these approaches continue to be a concern. 
We overcame these obstacles by using monoclonal antibody technology.  The BBM.1 
antibody, produced by mammalian cell culture, had the required affinity to lower β2m 
concentrations below the detectable limit of the radioimmunoassay.  We anticipate that this 
kind of affinity and specificity can be obtained using single chain antibody fragments (scFv) 
[Raag and Whitlow, 1995], which offer several potential advantages over whole antibodies 
(refer to Section 1.1).  Future research will focus on the development of anti-β2m scFv 
fragments and various immobilization chemistries to achieve a higher β2m binding site 
density.  Furthermore, the efficacy of the VFPR suggests that this technology could be 
tailored for the treatment of a range of pathologies characterized by elevated circulating 
concentrations of unwanted compounds, such as genetic disorders, liver failure, autoimmune 
disease, sepsis, or drug overdoses. 
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Figure 2.1 Diagram of the circuit used to study the clearance β2m of from human 
blood.  The whole blood path is shown in red, while regions accessible only to plasma 
are shown in gold.  The overall circulation flow rate was set at 200 mL/min, the plasma 
pump was calibrated to 50 mL/min, and the rotation rate was set at 1150 rpm.  The 
volume of the tubing running from the blood bag to the VFPR was 60 mL, while the 
return tubing was 5 mL.  The total reactor volume was 125 mL, which was distributed 
among the whole blood, adsorptive plasma, and plasma collection chambers as 50, 70, 
and 5 mL, respectively.  The volume of the plasma tubing was 10 mL.  The settled-
volume of agarose gel beads was 48 mL.  The blood temperature at the VFPR inlet and 
outlet was 35OC during the clearance of rβ2m.  The dimensions of this device prototype 
are given in Section 3.2.1. 
Figure 2.2 Dynamics of rβ2m clearance from human blood with a BBM.1-loaded 
VFPR, in vitro.  Error bars represent the standard error of the mean (SEM, N=4). 
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Chapter 3:  Macroscopic Mixing Model for the VFPR* 
3.1  INTRODUCTION 
 Effective extracorporeal removal of β2m from a patient will require the VFPR to 
exhibit favorable mass-transfer rates and to possess a sufficient binding capacity for β2m (up 
to 500 mg).  An accurate description of the macroscopic mixing pattern within the active 
plasma compartment (APC) of the VFPR is required if the mass-transfer characteristics of 
the fluidized particles are to be understood.  A macroscopic mixing model, previously 
developed to characterize the enzymatic degradation of heparin in the VFPR [Ameer et al., 
1999], has been unable to accurately describe the β2m-immunoadsorption data presented in 
Chapter 2.  Therefore, in this chapter, improved experimental methods and mathematical 
analyses are presented which provide a better understanding of the macroscopic mixing 
pattern within the VFPR.  These methods are used to characterize the mixing behavior of the 
prototype studied in Chapter 2 and a new, larger VFPR prototype.  By comparing the results 
from the two different device prototypes, the effect of increasing the size of the APC on 
mixing is assessed.  These results provide a better understanding of the VFPR as well as a 
framework for the development of a dynamic immunoadsorption model for the device, which 
is in described in Chapter 4. 
 
3.2  METHODS 
3.2.1  Reactor Prototypes 
 The small-scale prototype was identical to the one used in Chapter 2 and in the 
previous heparinase I experiments conducted by Ameer and co-workers [1999].  The new, 
larger VFPR prototype was constructed with a 22% longer and 90% thicker active 
compartment (Figure 3.1).  The compartmental volumes and pertinent length-scales of the 
two VFPR prototypes are compared by Table 3.1 and Table 3.2, respectively. 
                                                 
* Some of the material in this chapter has been reprinted from Chemical Engineering Science, Vol. 56, No. 18, 
“Modeling the mixing behavior of a novel fluidized extracorporeal immunoadsorber,” E. A. Grovender, C. L. 
Cooney, G. A. Ameer, R. S. Langer, 5437-5441, Copyright 2001, with permission from Elsevier [Grovender et 
al., 2001] (http://www.sciencedirect.com/science/journal/00092509).  Single copies of this chapter can be 
downloaded and printed only for the reader's personal research and study. 
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Prototype Blood Compartment 
Volume 
[mL] 
Active Plasma 
Compartment 
[mL] 
Plasma Collection 
Chamber 
[mL] 
Small 50 70   5 
Large 60 175 10 
 
Prototype Shaft 
Radius 
[cm] 
Membrane 
Radius 
[cm] 
Mesh 
Radius 
[cm] 
Membrane 
Length 
[cm] 
Mesh Length 
[cm] 
Small 2.70 2.86 3.20 11 6.4 
Large 2.70 2.86 3.49 14 6.4 
 
3.2.2  Residence Time Distribution Experiments 
 The RTD experiments were conducted by injecting a pulse of dye into the VFPR 
inlet, as depicted in Figure 3.2.  The outlet dye concentration measurements were taken from 
the blood and plasma ports during separate experiments and normalized to obtain the RTD 
function, E(t).  The injections of dye ranged from 0.5-2.0 mL, depending on the outlet port 
and prototype considered.  The dye was a 50 mg/mL aqueous solution of blue dextran (2,000 
kD).  The dye concentration measurements were made by reading the absorbance at 620 nm 
in a flow-cell cuvette using a spectrophotometer capable of real-time data acquisition 
(Shimatzu UV-1601).  The tubing connecting the VFPR to the spectrophotometer was treated 
as an ideal plug and was accounted for by subtracting the calculated residence time from the 
RTD data. 
 In accordance with the β2m-immunoadsorption experiments presented in Chapter 2, 
the main pump flowrate was set to 200 mL/min, the plasma pump flowrate was set to 50 
ml/min, and the shaft rotation rate was set at 1.2x103 rpm.  Additional RTD experiments 
were conducted with the plasma pump set at 100 mL/min.  To determine the effect of the 
fluidized particles on the mixing of the device, experiments were conducted at both plasma 
pump flowrates with and without of swollen polyacrylamide gel beads (90-180 µm diameter, 
Bio-Rad No. 150-4140).  This type of bead was selected because it effectively excludes blue 
Table 3.1  Comparison of the compartmental volumes of the two VFPR Prototypes. 
Table 3.2  Comparison of the pertinent length scales of the two VFPR Prototypes. 
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dextran from its pores.  The same 69% suspended volume fraction of gel beads was used in 
both prototypes (48 mL and 120 mL on a settled bed volume basis for the small and large 
prototypes, respectively). 
 
3.2.3  Mathematical Modeling 
 The macroscopic mixing behavior of each physical compartment within the VFPR is 
described using the standard tanks-in-series model [Levenspiel, 1999].  This model 
assumes that the real mixing pattern of a compartment can be described as a series of ideally 
well-mixed control volumes, or CSTRs (constant stirred tank reactors).  The residence times 
of fluid exiting the blood and plasma ports, τbport and τpport, are calculated by integrating the 
empirical RTD functions.  The number of CSTRs in the blood compartment, NBC, is 
determined by regressing the tanks-in-series analytical solution [Levenspiel, 1999] to the 
RTD of the blood port, Ebport(t). A key assumption of the standard tanks-in-series model is 
that the CSTRs have equal residence times.  Typically in this model the volumetric flowrate 
of fluid between CSTRs is constant, yielding a series of equal volume CSTRs.  However, the 
axial flowrate varies with axial position within the VFPRs blood compartment, due to the 
loss of flow across the microporous membrane.  Therefore, each theoretical CSTR in the 
blood compartment has a unique inlet flowrate, membrane surface area, and volume as 
shown by Figure 3.3. 
 It then follows that the residence time of each CSTR in the blood compartment, τBC,i, 
is described by Equation 3.1. 
  , 1,,
, , , 1
bport BC i i
BC i
BC m i BC i BC i
V V
N Q Q Q
τ
τ
−
= = =
+
 [3.1] 
Here VBC,i is the volume, Qm,i is the transmembrane volumetric flowrate, and QBC,i is the non-
transmembrane outlet volumetric flowrate of an arbitrary blood compartment CSTR.  The 
flow across the microporous membrane is assumed to be uniformly distributed, which yields 
Equation 3.2. 
  , ,mm i BC i
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V
 
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 [3.2] 
Here Qm is the total transmembrane, or plasma pump flowrate, and VBC is the total volume of 
the blood compartment, defined by Equation 3.3 (total conservation of volume within the 
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blood compartment).  The non-transmembrane outlet volumetric flowrate of an arbitrary 
blood compartment CSTR, QBC,i, is calculated by Equation 3.4 (incompressible flow). 
  ,
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Here QBC,0 is the VFPR inlet volumetric flowrate.  Equations 3.1, 3.2 and 3.4 are combined to 
yield Equation 3.5, 
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Equations 3.3 and 3.5 are used to calculate the blood compartment CSTRs in an iterative 
fashion. 
 The number of CSTRs in the active plasma compartment (APC), NAPC, is determined 
by regressing Equations 3.6-3.12 to the empirical RTD of the plasma port, Epport(t). 
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Here CBC,i and CAPC,i are the dye concentrations of arbitrary blood and plasma compartment 
CSTRs, respectively.  CPCC is the dye concentration in the plasma collection chamber, which 
is assumed to be one CSTR.  Thus, CPCC is also the dye concentration exiting the plasma 
port.  τAPC,i is the residence time of an arbitrary plasma compartment CSTR, while τPCC is the 
residence time of the plasma collection chamber.  These residence times are defined by 
Equations 3.9 and 3.10. 
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Here bulkAPCV  and is the volume of the active plasma compartment minus the volume of the 
bead spheres, while VPCC is the volume of the plasma collection chamber.  τAPC is the 
residence time of the entire APC (assuming that the dye is excluded from the gel bead pores).  
The average dye concentration flowing across the microporous membrane, mC , and the mean 
residence time of fluid flowing across the microporous membrane, τm, are defined by 
Equations 3.11 and 3.12. 
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 The value for bulkAPCV  is calculated from the specified values of VPCC and Qm and the 
calculated values of τm and τpport.  The initial conditions of the system of equations are: 1) the 
first blood compartment CSTR contains a finite amount of dye and 2) the remaining 
compartments contain no dye.  The model differential equations were integrated numerically 
using a fourth-order Runge-Kutta method. 
 
3.3  RESULTS AND DISCUSSION 
 Analysis of RTD curves can be a powerful tool for characterizing the real mixing 
patterns within a reaction vessel.  Using methods similar to those described in this chapter, 
two RTD data sets were previously obtained from the blood port of a prototype VFPR 
(plasma line connections shown in Figure 1.2 and Figure 3.2) [Ameer et al., 1999].  These 
separate data sets were used to gain preliminary insight into the mixing behavior of the APC 
during steady-state enzymatic reactions.  To mathematically simplify the VFPR model, the 
APC, collection chamber, and plasma line were treated as one compartment.  Furthermore, 
the RTD of fluid exiting the blood compartment through the microporous membrane was 
assumed to be identical to that exiting from the blood port.  These assumptions were not 
supported by the β2m-immunoadsorption data presented in Chapter 2.  Therefore, the 
development of a more rigorous compartmental model for the VFPR was deemed necessary.   
 In this chapter, experimental and modeling approaches are presented to better 
understand the mixing pattern within the VFPR and to assess the effects of gel loading and 
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changes in design specifications on mixing.  Figure 3.4 illustrates the mixing behavior of the 
blood compartments of the two prototypes, while Table 3.3 and Table 3.4 list the model 
parameters calculated from the blood port RTD data.  By comparing the values of τbport and 
NBC for the small prototype, it was concluded that the effect of loading gel beads into the 
APC on the blood compartments mixing pattern is negligible.  The same was assumed to be 
true for the large prototype, as the only difference in its blood compartment specifications 
was a 22% increase in membrane length. 
Qm 
[mL/min] 
Gel 
[mL] 
τbport 
[s] 
2
bportr  
[-] 
τm 
[s] 
NBC 
[-] 
VBC 
[mL] 
  50   0 14.6 0.9829 7.9 8 43 
  50 48 14.0 0.9912 7.6 8 41 
100   0 19.0 0.9817 9.8 7 48 
100 48 19.2 0.9786 9.9 7 48 
 
Qm 
[mL/min] 
Gel 
[mL] 
τbport 
[s] 
2
bportr  
[-] 
τm 
[s] 
NBC 
[-] 
VBC 
[mL] 
  50 0 17.8 0.9768 9.6 8 51 
 75 0 19.2 0.9784 10.4 8 52 
100 0 21.1 0.9717 10.7 8 53 
 
 Figure 3.5 illustrates the mixing patterns of fluid exiting through the plasma ports of 
the two prototypes, which were loaded with the same volume fraction of gel.  Table 3.5 and 
Table 3.6 list the model parameters calculated from the plasma port RTD data.  For a given 
prototype and flowrate, loading gel beads into the APC decreases the values of bulkAPCV  and 
τpport because the dye is excluded by the gel.  According the model regression, the bulk fluid 
volumes within the APC of each prototype essentially behave as single CSTRs (NAPC = 1, 
2
pportr  > 0.98) at the 50 mL/min plasma pump flowrate, regardless of gel loading.  Hence, it 
Table 3.3  Model parameters calculated from the blood port RTD data for the small 
VFPR prototype. 
Table 3.4  Model parameters calculated from the blood port RTD data for the large 
VFPR prototype. 
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was concluded that gel loading does not significantly affect macroscopic mixing at these 
process conditions.  At the 100 mL/min plasma pump flowrate, the bulk fluid volumes within 
the APC of each prototype essentially behave as single CSTRs (NAPC = 1, 2pportr > 0.95), 
provided that gel is not loaded.  However, at the 100 mL/min plasma pump flowrate, it was 
found that gel loading decreases mixing within the APC of each prototype (NAPC = 2, Figure 
3.5, flow visualization).  Therefore, it was concluded that the time-scale of mixing is 
modulated by the presence of the gel suspension when the plasma pump flowrate is doubled. 
The model is able to describe the plasma port RTD data from the large prototype better than 
that obtained from the small prototype with gel loaded at the 100 mL/min plasma pump 
flowrate ( 2pportr = 0.97 vs. 0.87, Figure 3.5).  This suggests that the increase in the time-scale 
of mixing, due to the increase in the radial thickness of the active compartment, is more than 
offset by the associated increase in residence time (τAPC).  Hence, the new VFPR prototype is 
expected to provide additional effective capacity for active gel particles and membrane 
surface area for increased plasma flowrates during blood detoxification.  Meanwhile, the 
large VFPR design only represents a small (10 mL) increase in the whole blood priming 
volume. 
Qm 
[mL/min] 
Gel 
[mL] 
τpport 
[s] 
2
pportr  
[-] 
τAPC 
[s] 
NAPC 
[-] 
bulk
APCV  
[mL] 
  50   0 108 0.9955 95 1 79 
  50 48 80 0.9966 66 1 55 
100   0 59 0.9807 46 1 77 
100 48 46 0.8671 33 2 55 
 
 Measuring the RTD at a plasma flowrate of 100 mL/min represents an extreme case 
that may not be clinically feasible for these prototypes; nevertheless, the model describes this 
condition moderately well.  For instance, the β2m-immunoadsorption experiments were 
performed with the small prototype at a plasma flowrate of 50 mL/min (Chapter 2) and the 
plasma separation rate of the device that was used for those studies is limited to 
approximately 60-70 mL/min.  Assuming that the maximum hemofiltration rate is 
Table 3.5  Model Parameters calculated from the plasma port RTD data for the 
small VFPR prototype. 
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proportional to the membrane surface area, the expected maximum plasma pump flowrate for 
the large prototype is 73-85 mL/min. 
 
Qm 
[mL/min] 
Gel 
[mL] 
τpport 
[s] 
2
pportr  
[-] 
τAPC 
[s] 
NAPC 
[-] 
bulk
APCV  
[mL] 
  50     0 226 0.9989 205 1 170 
  50 120 143 0.9860 122 1 102 
  75     0 158 0.9761 140 1 175 
  75 120 103 0.9410   84 1 106 
100     0 124 0.9596 107 1 178 
100 120   78 0.9711   62 2 103 
 
 In summary, RTD data sets were collected from the plasma and blood ports 
separately for the studies presented in this chapter.  The new model treats each physical 
compartment within the VFPR individually.  It also accounts for, at least partially, the 
differences in RTD of the fluid exiting the blood compartment through the blood port and the 
microporous membrane. The model regression revealed that the bulk fluid within the APC 
was well-mixed (NAPC = 1) at a plasma pump flowrate of 50 ml/min, with or without gel 
beads.  The results of this study will be incorporated into a dynamic adsorption model for the 
VFPR (Chapter 4).   
 
Table 3.6  Model Parameters calculated from the plasma port RTD data for the 
large VFPR prototype. 
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Figure 3.1  Photograph of the new, larger VFPR prototype.  The device is partially 
disassembled for display purposes.  The compartment volumes and pertinent length 
scales are provided in Table 3.1 and Table 3.2. 
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Figure 3.2  Schematic diagram of the experimental setup used to obtain RTDs from 
the plasma port.  The spectrophotometer was moved to the blood port to obtain the 
RTDs of the blood compartment (not shown). 
Figure 3.3  The compartmental mixing model for the VFPR. 
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Figure 3.4  Blood port residence time distribution functions for the small (top: a,b) 
and large (bottom: c,d) VFPR prototypes at plasma pump flowrates of 50 (left: a,c) 
and 100 (right: b,d) mL/min.  The average data sets (N=3, SEM < 0.0025 s-1) and 
model curves are shown for the experiments conducted without gel loaded into the active 
plasma compartment. 
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Figure 3.5  Plasma port RTD curves for the small (top: a,b) and large (bottom: c,d) 
VFPR prototypes at plasma pump flowrates of 50 (left: a,c) and 100 (right: b,d) 
mL/min.  The average data sets (N=3, SEM < 0.0005 s-1) and model curves are shown 
for the experiments conducted with gel loaded into the active plasma compartment. 
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Chapter 4:  Immunoadsorption Model for the VFPR* 
4.1  INTRODUCTION 
 From an engineering perspective, it would be useful to have a dynamic 
immunoadsorption model for the VFPR to aid in the design of device prototypes, in vitro 
experiments, and potential clinical trials.  To derive such a model, the mass-transfer and 
adsorption processes within the VFPR need to be described.  Towards this end, experimental 
and mathematical methods for characterizing the macroscopic mixing pattern within an 
immunoadsorptive VFPR were described in Chapter 3.  In this chapter, the equilibrium 
behavior of immunoadsorptive gel beads is characterized using the Langmuir adsorption 
isotherm and confocal microscopy.  Furthermore, the importance of external mass-transfer 
resistances within the active plasma compartment (APC) is assessed through dissolution 
studies conducted with benzoic acid particles.  These results are used to develop a dynamic 
immunoadsorption model that describes the performance of the immunoadsorptive VFPR 
without using any adjustable parameters. 
 
4.2  IMMUNOADSORPTIVE GEL 
 Thus far, the immunoadsorptive media used with VFPR devices has consisted of anti-
β2m monoclonal antibodies immobilized onto 4% agarose gel beads (Chapter 2).  In this 
section, the partitioning, diffusion, and adsorption of β2m within the immunoadsorptive gel 
beads is described.  These characteristics of the immunoadsorbent are used later in the 
derivation and solution of the dynamic immunoadsorption model equations for the VFPR. 
 
4.2.1  Solute Partitioning 
 The partition coefficient of β2m in the gel (Φ) is defined on a total bead volume basis 
by Equation 4.1.  The value of this parameter is estimated using Equation 4.2, a relation 
derived by Ogston [1958] for dilute solutions of uncharged, spherical macromolecules in an 
array of randomly arranged cylindrical fibers.  
                                                 
* This chapter is a revised version of a research article originally published in the AIChE Journal [Grovender et 
al., 2002].  It has been reproduced with permission of the American Institute of Chemical Engineers.  Copyright 
© 2002 AIChE.  All rights reserved. 
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  gel
bulk
C
C
Φ ≡  [4.1] 
  
2
exp 1 s
f
r
r
φ
  
 Φ = − +     
 [4.2] 
Here Cbulk is the concentration of desorbed β2m in the bulk fluid, Cgel is the concentration of 
desorbed β2m inside the beads on a total gel volume basis, and φ is the volume fraction of 
polymer fibers within the gel beads (φ = 0.04).  The average radius of the agarose fibers, rf, is 
taken to be 1.9x10-9 m, which was the value measured by Djabourov and co-workers [1989] 
using small-angle X-ray scattering.  The hydrated radius of β2m, rs, was estimated to be 
1.7x10-9 m by assuming that β2m has the specific volume and degree of hydration of a typical 
globular protein [Cantor and Schimmel, 1980]. 
 
4.2.2  Adsorption Isotherm 
 The antigen-antibody equilibrium dissociation constant, KD, is defined by Equation 
4.3, while an adsorption site mass-balance is given by Equation 4.4.  The combination of 
Equations 4.1, 4.3, and 4.4 results in the Langmuir adsorption isotherm, Equation 4.5. 
  
2
eq eq
s gel
D eq
m
C
K
β
ρ
ρ
≡  [4.3] 
  
2
0 eq eq
s s mβρ ρ ρ= +  [4.4] 
  
2
00 eqeq
s geleq s bulk
m eq
eqD D gel
bulk
CC
K K CC
β
ρρρ = =
++
Φ
 [4.5] 
On a total gel volume basis ρs and 2mβρ  are the densities of adsorption sites and adsorbed 
β2m, respectively. This is in contrast to the to the settled-bed volume basis that was used to 
define ρ′s for Equation 2.1.  The superscripts 0 and eq refer to the initial and equilibrium 
values, respectively.   
 A β2m mass-balance (Equation 4.6) can be used with Equations 4.1 and 4.5 to obtain 
Equation 4.7, a form of the Langmuir adsorption isotherm in terms of measurable variables.   
  [ ] [ ]
2
0 0(1 ) (1 ) (1 )eq eq eqbed m total bed bulk bulk bed gel gelV V V C C V C Cβε ρ ε ε   − = − − − + − −     [4.6] 
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  ( ) 00(1 )(1 ) (1 ) eqeqtotal bed s bulkbulk bulk
eqDbed
bulk
V V CC C KV C
ε ε ρ − − −Φ −
− = 
  +
Φ
 [4.7] 
Here Vtotal is the total volume of the system, Vbed is the settled-bed volume of 
immunoadsorbent, and ε is the settled-bed void fraction.  For cases when Φ~1 or Vbed << 
Vtotal, the left hand side of Equation 4.7 can be approximated as in Equation 4.8. 
  ( ) ( )0 0(1 )(1 ) eq eqtotal bed totalbulk bulk bulk bulk
bed bed
V V VC C C C
V V
ε   − − −Φ
− ≈ −   
   
 [4.8] 
For the values of the parameters considered herein, this approximation represents an error of 
less than 2%.  The adsorption site density ( 0sρ ) of the immunoadsorptive gel was determined 
in Chapter 2 by equilibrating samples with saturating amounts of β2m (where ρ′s = [1-ε] 0sρ ).  
The same protocol and batch of immunoadsorbent was used with three sub-saturating 
quantities of β2m to produce additional data, from which the value of KD was regressed by 
minimizing SSE (Sum Squared Error). 
 
4.2.3  Adsorption Site Distribution 
 Confocal microscopy* was used to assess the spatial distribution of β2m-adsorption 
sites within the immunoadsorbent gel beads.  Recombinant human β2m was prepared using 
the protocol described in Chapter 2 and labeled with fluorescein-5-EX succinimidyl ester, 
according to the instructions provided by the manufacturer (Molecular Probes, Eugene, OR).  
Fluorescein-β2m (6 mg) was equilibrated with a sample of the immunoadsorptive gel (0.20 
mL) in phosphate buffered saline (pH 7.4; PBS).  The sample was combined with an equal 
volume of anti-bleaching buffer (10 µg p-phenylene diamine, 1.5 mL deionized water, and 1 
mL 10x PBS brought to a total volume of 10 mL with glycerol) and studied with a Zeiss 
LSM 510 confocal microscope (Oberkochen, Germany).  Two additional samples were 
analyzed as controls: 1) gel beads without immobilized antibody, but equilibrated with 
fluorescein-β2m and 2) gel beads with immobilized antibody, but not equilibrated with 
fluorescein-β2m. 
                                                 
* This work was conducted utilizing  the W. M. Keck Foundation Biological Imaging Facility at the Whitehead 
Institute. 
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4.2.4  Effective Diffusivity 
 The effective diffusivity (De) of β2m inside the gel beads was calculated using 
Equation 4.9, where Dw is the diffusion coefficient of β2m in dilute aqueous solution and θ is 
the diffusion hindrance exerted by the gel polymer fibers.  
  e wD Dθ=  [4.9] 
The value of Dw was estimated at 37OC (1.8x10-10 m2/s) using a correlation for large 
molecules including proteins [Polson, 1950] and θ was assumed to be the measured value 
(0.63) reported by Johnson and co-workers [1996] for lactalbumin (a 1.4x104 g/mol globular 
protein) in 4% agarose gel. 
 
4.3  DEVICE MODEL 
4.3.1  Blood Compartment 
 Figure 4.1 illustrates the dynamic adsorption model for the VFPR.  Through residence 
time distribution studies and mathematical modeling it was shown in Chapter 3 that the 
macroscopic mixing behavior within the blood compartment can be well represented by a 
series of  NBC  ideally well-mixed tanks.  The residence time (τBC,i) of blood plasma in each 
tank is constant, but each tank has its own unique volume (VBC,i).  Equations 4.10-4.14 
represent a mass balance of β2m within the blood compartment, taking into account 
hemofiltration into the APC. 
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,
1BC i
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dt τ −
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  , , 1 ,BC i BC i m iQ Q Q−= −  [4.14] 
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Here CBC,0 , HBC,0 and QBC,0 are the inlet plasma β2m concentration, hematocrit (volume 
fraction of blood cells), and whole blood volumetric flowrate, respectively.  The plasma 
pump controls the total volumetric flowrate of plasma across the microporous membrane into 
the active compartment, Qm.  For the ith tank-in-series, CBC,i is the plasma concentration of 
β2m, HBC,i is the hematocrit, QBC,i is the outlet volumetric flowrate of whole blood, and Qm,i is 
the volumetric flowrate of plasma across the membrane.  The total volume of the blood 
compartment is VBC.   The β2m concentration of plasma crossing the membrane, mC , is given 
by Equation 4.15.   
  ( ), ,
1
1 BCN
m BC i BC i
iBC
C V C
V
=
= ∑  [4.15] 
 
4.3.2  Active Plasma Compartment (APC) 
 The APC houses the immunoadsorptive media, which consists of an antibody 
immobilized onto porous agarose gel beads.  The model for the APC incorporates the 
following assumptions: 1) the intrinsic antibody-antigen association rate is instantaneous, 2) 
the adsorption sites are uniformly distributed inside the gel beads, 3) the adsorption 
equilibrium follows the Langmuir isotherm, 4) the bulk fluid within the APC behaves as a 
single well-mixed control volume (Chapter 3), and 5) the size of the gel beads can be well 
represented by the volume-average radius, R. 
 Equation 4.16 represents a mass balance for β2m in the bulk fluid of the APC. The 
first term on the right-hand side of Equation 4.16 accounts for convective flow through the 
APC; the second term accounts for transport of β2m to the surface of the active beads.   
  ( ) ( ) ( )1 surfaceAPCAPC bed m m APC surface m APC APCdCV V Q C C A k C Cdtε− − = − + −    [4.16] 
Here VAPC is the total volume of the APC and mk  is the mass-transfer coefficient for the 
transport of β2m from the bulk fluid to the surface of the gel beads.  The β2m concentrations 
within the bulk fluid and at the outer surface of the gel beads are CAPC and surfaceAPCC , 
respectively.  The total surface area of the gel, Asurface, is expressed by Equation 4.17 in terms 
of previously defined parameters, where Nbeads is the total number of gel beads in the APC. 
 64 
  ( ) ( )2 23(1 ) 3(1 )4 4(4 3)bed bedsurface beads
V VA N R R
R R
ε ε
π π
π
 − −
= = = 
 
 [4.17] 
Equations 4.1, 4.16, and 4.17 are combined to yield Equation 4.18 which, along with 
Equations 4.19 and 4.20, are used to model dynamics of the β2m concentration of the bulk 
fluid within the APC.  
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τ =  [4.20] 
Here the characteristic time-scale of external mass-transfer (or the transport of β2m to the 
surface of the active beads) is τEMT and τAPC is the residence time of the bulk fluid volume. 
 Using the aforementioned assumptions, the species conservation equation for 
desorbed β2m within an immunoadsorptive gel bead is reduced to the form shown by 
Equation 4.21.  The rate of adsorption, Radsorption, is expressed in the convenient form shown 
by Equation 4.22. 
  22
1gel gel
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C C
D r R
t r r r
∂ ∂ ∂
= − ∂ ∂ ∂ 
 [4.21] 
  2m geladsorption
gel
C
R
C t
βρ∂ ∂ 
=  ∂ ∂ 
 [4.22] 
 The Langmuir adsorption isotherm, or Equation 4.5, is combined with Equations 4.21 
and 4.22 to yield Equations 4.23 and 4.24 which represent a mass balance for β2m within a 
gel bead. Here the characteristic time-scale of internal mass-transfer within the porous beads 
is τIMT .  Equation 4.23 has previously been derived and used to model the adsorption of 
albumin onto ion exchange resin [Leaver et al., 1992].  Equations 4.25 and 4.26 represent the 
boundary conditions that were used to solve Equation 4.23, where the superscripts surface and 
center refer to their respective radial postions. 
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4.3.3  Plasma Line, Collection Chamber, and Blood Outlet Port 
 The plasma line and collection chamber are lumped together as a single well-mixed 
control volume and modeled by Equations 4.27-4.28.  Here CPLCC , VPLCC, and τPLCC are the 
lumped β2m concentration, volume, and residence time, respectively.  The plasma β2m 
concentration of partially cleansed whole blood exiting the VFPR, CVFPR, is calculated by 
Equation 4.29. 
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4.4  RESERVOIR MODEL 
 The VFPR is usually connected to a β2m reservoir in a closed-loop circuit for blood 
detoxification (Figure 4.2).   This reservoir can be comprised of a bag of donated blood, an 
animal model, or a human patient.  To date, β2m-immunoadsorption experiments with the 
VFPR have been limited to bags of whole human blood (Chapter 2).  Equations 4.30 and 
4.31 represent the mass balance of β2m in a blood bag (530 mL) and its circuit tubing (65 
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mL). These two volumes are lumped together as VBR.  Equations 4.32 and 4.33 
mathematically connect the reservoir to the VFPR device in a closed-loop circuit.  
  ( ), , 1 ,
,
1BR i
BR i BR i
BR i
dC
C C
dt τ −
= −  [4.30] 
  , BR BRBR i
BR BR BR
V
N N Q
τ
τ = =  [4.31] 
  ,0BR VFPRC C=  [4.32] 
  ,0 , BRBC BR NC C=  [4.33] 
Here NBR is the number of theoretical tanks representing VBR.  For the ith tank-in-series, CBR,i 
is the plasma β2m concentration and τBR,i is the residence time. 
 
4.5  CHARACTERIZATION OF MASS-TRANSFER TO THE SURFACE OF 
SUSPENDED PARTICLES  
 The importance of mass-transfer resistance at the external surface of the suspended 
gel beads (τEMT, Equation 4.20) relative to the mass-transfer resistance associated with the 
hemofiltration rate (τAPC, Equation 4.19) was assessed through dissolution studies conducted 
with small, non-spherical particles of benzoic acid.  These particles were created using a 
method similar to one previously described by Moore [1994].  Briefly, benzoic acid was 
melted, solidified into a flat sheet on aluminum foil, and crushed with a ceramic mortar and 
pestle.  Irregularly shaped particles approximately 100 µm in size were obtained by sifting 
the crushed benzoic acid between 150 µm and 75 µm nominal opening stainless steel sieves 
(VWR, Westchester, PA).   
 The dissolution studies were conducted as shown in Figure 4.3.  The active plasma 
compartment was flushed for 5 minutes (>3.5 residence times) to remove most (>95%) of the 
dissolved benzoic acid that was injected along with the solid particles.  During the following 
5 minute experimental period, samples were taken every 60 seconds and immediately filtered 
to remove any remaining fine particles (0.45 µm Millipore catalog number SLHV R04 NL, 
Bedford, MA).  The concentration of benzoic acid was measured by reading the absorbance 
at 250 nm (diluting the samples as necessary with 0.01% Triton X-100).  
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4.6  COMPUTATIONAL METHODS  
 Equations 4.10-4.15, 4.18-4.20, and 4.23-4.33 model the dynamics of β2m adsorption 
within the VFPR and the subsequent removal of β2m from a blood reservoir.  The Forward-
Time Centered-Space (FTCS) method was used to convert Equation 4.23 into a discrete form 
(200 finite radial sections) and the second-order Runge-Kutta algorithm was applied to 
integrate the differential equations [Press et al., 1992].  Input parameters (including initial 
conditions, with superscripts t=0) used for the model calculations are listed in Table 1.  At 
each time-step, the total mass-balance error for Equations 4.10-4.15, 4.18-4.20, and 4.23-4.33 
was kept below 0.5%.  A copy of the FORTRAN program used to perform the model 
calculations is provided in the Appendix. 
 
4.7  RESULTS AND DISCUSSION 
 The VFPR is a multi-compartment Taylor-Couette flow hemofilter designed to 
remove toxins from a patients blood stream via heterogeneous adsorption or reaction.  The 
first immunoadsorption application has been the removal of the amyloid-associated protein 
β2-microglobulin from human blood in vitro.  This technology, we believe, can be used for 
understanding and treating the progression of Dialysis-Related Amyloidosis, a devastating 
complication of long-term kidney failure, by targeting a specific macromolecule and 
monitoring the effect of its removal on the patient via clinical trials.  To lay a solid 
foundation for the derivation of a dynamic model, the equilibrium behavior of the 
immunoadsorbent and the mass-transfer characteristics of the VFPR were investigated 
independently.   
 Over the β2m concentration range considered, the Langmuir isotherm describes 
equilibrium β2m adsorption data (Figure 4.4).  The value of the antibody-antigen dissociation 
constant (KD = 0.1 ± 0.1 mg/L) is significantly smaller than the lower limit of the β2m 
concentration range (1.0 - 3.0 mg/L) in the circulation of healthy individuals [Floege and 
Ketteler, 2001].  Therefore, this model immunoadsorbent appears to have sufficient affinity 
for therapeutic application.   
 The cross-sectional confocal micrograph of a typical immunoadsorptive gel bead 
shows that the β2m adsorption sites are uniformly distributed throughout the polymer  
(Figure 4.5a).  This was a key assumption in the numerical solution of Equation 4.23 (i.e. 
 68 
0
sρ is not a function of radial position).  Meanwhile, the defect in the atypical bead 
demonstrates the ability of the imaging technique to detect regions inside the gel that lack 
adsorbed β2m (Figure 4.5b).  These results demonstrate the utility of confocal microscopy for 
the characterization of porous matrices.  
 During the dissolution studies the observed concentration of benzoic acid (3.0±0.1 
g/L) exiting the VFPR through the plasma line did not significantly differ from the solubility 
limit (2.9 g/L at 20oC) [Budavari et al., 1989].  This strongly suggests that external mass-
transfer resistances within the active plasma compartment are not rate limiting under the 
process conditions considered.  In order to provide flexibility for other process conditions 
that may arise in the future, the derivation of the VFPR model accounts for the possibility of 
a rate-limiting external mass-transfer resistance through the mass-transfer coefficient, mk .  In 
accordance with the findings of the dissolution studies, mk  was assigned a finite value 
sufficiently large such that τEMT  << τIMT and τEMT  << τAPC (Table 4.1 and Equations 4.19, 
4.20, and 4.24).  Thus, external mass-transfer resistance did not have any appreciable effect 
on the immunoadsorption dynamics calculated by the model for the experiment considered 
(refer to the sensitivity analysis below and Figure 4.7a).  However, the second term on the 
right-hand side of Equation 4.18 is required in any case to account for the transport of β2m to 
the surface of the gel beads.  
 The models ability to describe VFPR performance was tested with a set of input 
parameters corresponding to a previously conducted β2m-adsorption experiment (Table 4.1).  
Without adjusting any of the parameters, the dynamic immunoadsorption model is able to 
describe the performance of the VFPR (Figure 4.6, Equations 4.10-4.15, 4.18-4.20 and 4.23-
4.33).  It is important to note that the equilibrium concentration of β2m is on the order of the 
antibody-antigen dissociation constant (KD).  This is the case because the system was 
charged, approximately, with a 1:1 stoichiometric ratio of β2m and adsorption sites.  Under 
clinical operating conditions, an immunoadsorptive VFPR would likely contain an excess 
number of adsorption sites.  In separate β2m immunoadsorption experiments that were 
conducted with excess adsorption sites, the equilibrium β2m concentrations were below 
detectable limits (Chapter 2). 
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Parameter Value Units Parameter Value Units 
0t
APCC
=  0 mg/L Qm 50* mL/min 
0
,
t
BC iC
=  3.2* mg/L R 46   
0
,
t
BR iC
=  3.2* mg/L VBC 46.5§, mL 
0t
gelC
=  0 mg/L VBC,i 6.6, 6.3, 6.1, 5.9 mL 
0t
PLCCC
=  0 mg/L         5.7, 5.5, 5.3, 5.1§,  
De 1.1 x10-10 m2/s VAPC 79§ mL 
HBR 0.31 - Vbed 48* mL 
KD 0.1 mg/L VBR 595* mL 
mk  10
-3 m/s VPLCC 15* mL 
NBC 8§, - ε 0.4** - 
NBR 3§, - Φ 0.87 - 
QBR 200* mL/min 0sρ  50*, mg/L 
 
 A sensitivity analysis was conducted on the external mass-transfer coefficient ( mk ) to 
confirm that increasing the value of mk  above the arbitrarily assigned value does not have a 
significant effect on the model predictions (Figure 4.7a).  Furthermore, the models 
flexibility to account for external mass-transfer resistances is demonstrated by the shape of 
the plasma line model curve for the low value of mk (τEMT  ∼ τIMT).  The assumption that the 
population of gel beads can be well represented by the volume-average radius was tested by a 
sensitivity analysis on R (Figure 4.7b).  Varying the value of this parameter by one standard 
of deviation has an effect on the shape of the plasma line concentration curve; however, this 
                                                 
* Chapter 2 [Ameer et al., 2001] 
 Data provided by the manufacturer. 
 After accounting for dilution by the priming saline. 
§ Chapter 3 [Grovender et al., 2001] 
** Calculated from the total and void volumes measured in a packed column (acetone and pore-excluded 
aggregate protein markers; Bio-Rad #151-1901, Hercules, CA). 
 The mixing behavior was re-characterized through similar RTD studies using a 36% glycerol-in-water 
solution at 20OC to better account for the viscosity and density of whole blood [Wolf et al., 1984; Fournier, 
1999]. 
 Value previously reported on a settled-bed volume basis. 
Table 4.1  Model input parameters. 
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effect is reasonably symmetric.  Therefore, the assumption appears to be justified.  Because 
their values were estimated from the literature, sensitivity analyses on the hindered effective 
diffusivity (De) and the solute partition coefficient (Φ) were performed (Figure 4.7c-Figure 
4.7d).  The variations considered (refer to Figure 4.7 caption) in De and Φ resulted in changes 
of less than 15% in the calculated values of CPLCC at all time-points.  
 The dynamic immunoadsorption model for the VFPR was developed to facilitate the 
development of the device and the optimization of its potential therapeutic application.  With 
the desire for a model capable of describing the VFPRs performance over a range of 
conditions, the model was based on fundamental transport theory and guided by the 
independent characterization of the fluid dynamics and adsorption equilibrium.  The model 
calculations predict that the mass-transfer processes within the active compartment of the 
VFPR do not control the rate of β2m-adsorption (Figure 4.7).  Hence, we conclude that the 
process controlling the β2m-adsorption rate within the VFPR is the hemofiltration rate (Qm = 
50 mL/min), which is on the order of the reported flowrate of extravascular β2m into the 
blood stream (approximately 70 mL/min) [Floege et al., 1991].  These two processes are 
expected to be rate-controlling for β2m removal from a patient with the immunoadsorbent 
VFPR.  A major goal for the future development of the VFPR will be to increase the 
hemofiltration rate while maintaining the fast mass-transfer rates within the active plasma 
compartment.  The methods for characterizing the VFPR and the dynamic immunoadsorption 
model presented herein should prove useful in this endeavor.   
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Figure 4.1  Schematic diagram of the dynamic VFPR adsorption model.  The 
macroscopic mixing behavior of the blood compartment is described by a finite series of 
ideally well-mixed control volumes or tanks.  The bulk fluid of the active plasma 
chamber and the lumped volume of the plasma line tubing & plasma collection chamber 
are each represented by a single tank. 
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Figure 4.2  Closed-loop blood detoxification with the VFPR.  The β2m reservoir 
represents either a human patient or a substituted model (i.e. a bag of blood) and the 
circuit tubing.  The equations shown are provided as a convenience to the reader and are 
described throughout the text. 
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Figure 4.3  Apparatus used to conduct the dissolution studies.  Agarose gel beads (40 
mL Sepharose® CL-4B) were included in the active compartment in an attempt to 
duplicate the conditions of the dynamic β2m-adsorption experiments.  The main pump 
flowrate (200 mL/min), plasma pump flowrate (50 mL/min), and cylinder rotation rate 
(1.2 x103 rpm) also matched those used during the β2m-adsorption experiments.  
Aggregation of the benzoic acid particles was prevented by adding 0.01% Triton X-100 
to the system.  It has previously been reported that the use of a similar non-ionic 
surfactant during benzoic acid dissolution studies has a minimal effect (<5%) on the 
mass-transfer rate [Gondoh et al., 1968].   
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Figure 4.4  Equilibrium adsorption behavior of the immunoadsorptive media.  
Equations 4.7 and 4.8 were regressed to the saturated (Chapter 2) and sub-saturated data 
to determine the value of KD (0.1 ± 0.1 mg-β2m /L ~ 10 nmol-β2m /L).  The value of ρs0 
(50 ± 3 mg-β2m/L-gel) was calculated from the saturated data (reported as ρ′s = 30 ± 2 
mg-β2m/L-settled-bed in Chapter 2).  The controls did not show significant fluorescence.  
Error bars and confidence intervals represent the standard error of the mean (SEM). 
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Figure 4.5  Confocal micrograph of the immunoadsorptive gel: center cross-section 
of a typical bead (a) and an atypical bead (b).  β2m is shown in green. The controls 
showed no apparent adsorption of β2m or intrinsic fluorescence of the immunoadsorbent.  
The thickness of the cross-section shown is 0.40 µm and the resolution is 0.22 µm. 
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Figure 4.6  The predicted and observed dynamics of β2m clearance from whole 
blood by an immunoadsorptive VFPR, in vitro.  The model equations listed in Figure 
4.2 and the input parameters listed in Table 2.1 were used to calculate the blood reservoir 
outlet and plasma line β2m concentrations.  The blood reservoir outlet and plasma line 
data was first presented in Chapter 2.  Error bars represent the standard error of the mean 
(SEM). 
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Figure 4.7  Sensitivity analysis results for the model parameters mk (a), R (b), De (c), 
and Φ (d).  The plasma line data (∆) was taken from Chapter 2 [Ameer et al., 2001] and 
the error bars represent the standard error of the mean (SEM).  The center values for the 
model parameters are listed in Table 4.1.  The high and low values are as follows: 
mk = 10
-
2 & 10-5 m/s, R = 58 & 34 µm(±σ ), De = 1.8x10-10 & 0.7x10-10 m2/s (±20%), Φ = 1.00 & 
0.75 (the measured value reported Johnson and co-workers [1995] for lactalbumin in 6% 
agarose gel). 
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Chapter 5:  ScFv-Based Immunoadsorbent 
5.1  INTRODUCTION 
In Chapter 2, a model anti-β2m immunoadsorbent was created by immobilizing whole 
BBM.1 antibodies onto porous agarose gel beads.  While the molar binding activity of the 
immobilized BBM.1 antibody was lower than expected (6%), its β2m-adsorption site density 
(ρ′s = 0.030 ± 0.002 mg-β2m/mL-settled-gel) was sufficient to conduct preliminary in vitro 
research with a VFPR prototype.  The ideal immunoadsorbent for this application should 
possess a high β2m-adsorption site density (ρ′s >1 mg-β2m/mL-settled-gel), so as to reduce 
the hold-up and/or loss of valuable plasma proteins during extracorporeal therapy.  Single-
chain variable region antibody fragments (scFv) should theoretically allow for higher 
effective β2m-adsorption site densities because they are smaller in size than whole 
antibodies.  ScFvs are also genetically defined and amenable to microbial expression and in 
vitro evolution.  These potential advantages of scFvs over whole antibodies motivated the 
creation of the BBM.1 scFv-based immunoadsorbent that is described by this chapter.   
 
5.2  METHODS 
5.2.1  Labeling of β2m  
 Recombinant human β2m was prepared as previously described [Ameer et al., 2001] 
and biotinylated using the FluoReporter® Biotin-XX protein labeling kit (Molecular Probes, 
Eugene, OR).  A 20 mg/mL working stock of biotin-XX (sulfosuccinimidyl ester, sodium 
salt) in DMSO (dimethylsulfoxide) was prepared and a 10-fold molar excess was added to 
1.6 mg/mL β2m in PBS 7.4 (phosphate buffered saline, pH 7.4:  10 mM PO4, 138 mM NaCl, 
2.7 mM KCl). The labeling reaction was performed at this pH to inhibit the reaction of the 
sulfosuccinimidyl ester with the primary amines of lysine residues, thereby favoring the 
labeling of the β2m at the N-terminus.  The reaction mixture was incubated on a rocker for 90 
min at room temperature and subsequently dialyzed overnight into PBS 7.4 at 4oC to remove 
any unreacted biotin-XX using a 6-8 kD membrane (Spectrum Laboratories, Rancho 
Dominguez, CA).  The final concentration of β2m was determined using an extinction 
coefficient of 20,065 M-1 cm-1 at 280 nm as previously described [Ameer et al., 2001], while 
the degree of biotinylation (0.93 mol-biotin/mol-β2m) was determined following the kit 
instructions. 
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 Recombinant human β2m was labeled with Alexa Fluor® 488 (carboxylic acid, 
succinimidyl ester), a fluorophore that is spectrally similar to fluorescein, but possesses 
greater brightness and photostability (Molecular Probes).  The protocol used was essentially 
that described above for the biotinylation of β2m.  However, 3-fold molar excess of a 5 
mg/mL working stock of labeling agent was added to 1.1 mg/mL of β2m in PBS 7.4 for the 
labeling reaction.  The final concentration and degree of labeling (0.056 mole-
fluorophore/mole-β2m) was determined using the extinction coefficient previously described 
[Ameer et al., 2001] and the protocol provided by Molecular Probes. 
 
5.2.2  Cloning of VH and VL genes   
The BBM.1 antibody-producing hybridoma cell line (HB-28) was purchased from 
ATCC (Manassas, VA) and grown in T-flask static culture at 37oC in a 5% CO2 atmosphere.  
The growth media consisted of 90% RPMI 1640 medium (ATCC), 10% FBS (fetal bovine 
serum), 100 u/mL penicillin, and 0.1 mg/mL streptomycin.  The total RNA from 3x107 cells 
was isolated and RT-PCR was performed using the RNeasy® Midi and the OneStep RT-PCR 
kits from Qiagen (Valencia, CA).  Various combinations of the primers (0.5 µM each) 
provided in the Mouse Ig-Primer Set (Novagen, Madison, WI) were used along with 1 µg of 
RNA and 40 units of RNase inhibitor (Promega, Madison, WI) in 50 µL RT-PCR reaction 
volumes.  The thermocycler was run for 1 reverse-transcription cycle of 30 min at 50oC, 1 
DNA polymerase-activation cycle of 15 min at 95oC, 35 amplification cycles of 45 sec at 
94oC, 1 min at 60oC, 1 min at 72oC and 1 final extension cycle of 10 min at 72oC.   
The PCR products were run on 1.2 or 2.0% agarose gels stained with ethidium 
bromide.  Those displaying bands characteristic of VH and VL genes (about 500 base pairs in 
length) were purified using the QIAquick kit (Qiagen) and ligated into the pSTBlue-1 
plasmid (Novagen).  The ligation products were used to transform NovaBlue SinglesTM 
competent cells (included in the pSTBlue-1 Perfectly Blunt Cloning kit from Novagen), 
which were plated onto LB (Luria-Bertani medium) agar plates containing 50 mg/mL 
ampicillin.  After incubating the plates overnight at 37oC, single colonies were each grown in 
5 mL of LB containing 100-150 mg/L ampicillin at 37oC overnight, and their plasmids were 
purified using the QIAprep® Spin Miniprep kit (Qiagen).  The DNA inserts of the plasmid 
clones were sequenced and translated into peptide sequences so that they could be compared 
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to the partial peptide sequences obtained through the N-terminal degradation of protein A-
purified BBM.1 antibody. 
Twenty-two cycles of N-terminal degradation were performed on a sample of whole 
BBM.1 antibody.  For each degradation cycle, the two predominant residues were assigned to 
one of two peptide chains based on a match with the published sequence of the MOPC-21 
myeloma κ light chain [Svasti and Milstein, 1972].  This was done because the BBM.1 
hybridoma cell line (HB-28) was created by fusing an anti-β2m B-cell with the X63-Ag8 
myeloma [Brodsky et al., 1979], a descendent of the MOPC-21 myeloma [Kohler and 
Milstein, 1975].  Both the X63-Ag8 and MOPC-21 myeloma cell lines have been shown to 
secrete the MOPC-21 κ light chain as well as an IgG1 heavy chain [Kohler and Milstein, 
1975].   
 
5.2.3  Display of scFv fragment by yeast 
 The VH and VL genes cloned from the BBM.1 hybridoma were initially expressed as 
a scFv fragment in a yeast display system [Boder and Wittrup, 1997] (Figure 5.1).  This 
approach was selected because the β2m-binding affinity of the scFv could readily be 
characterized in a quantitative fashion and, if deemed necessary, would be in a vector that is 
amenable to in vitro evolution [Boder et al., 2000]. 
 
5.2.3.1  Insert Assembly  
The scFv DNA insert was assembled in a VH-(Gly4Ser)4-VL configuration via the 
splicing by overlap extension (SOE) method [Horton et al., 1989].  All of the PCR reactions 
were performed using Cloned Pfu DNA polymerase and Cloned Pfu Reaction Buffer 
(Stratagene, La Jolla, CA), following the manufacturers instructions except where otherwise 
noted.  During the first round of PCR, the VH and VL DNA inserts were amplified from the 
pSTBlue-1 plasmids (30 ng plasmid DNA in each 50 µL reaction volume) using the custom 
primers shown in Figure 5.2 (0.2 µM each).  The thermocycler was run for 1 cycle of 45 sec 
at 98oC, 28 cycles of 45 at 98oC, 90 sec at 72oC, and 1 cycle of 10 min at 72oC.  The resulting 
VH and VL PCR products were purified using the QIAquick® Kit and quantitated by 
measuring their absorbance at 260 nm. 
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The second round of PCR was initiated without primers and was performed in a 
single 50 µL reaction volume with 77 ng of each VH and VL PCR product and 400 µM of 
each dNTP (deoxynucleotide triphosphate).  The thermocycler was run for 5 cycles of 1 min 
at 96oC, 1 min at 53oC, 2 min at 72oC, and 1 cycle of 10 min at 72oC.  The 5-VH and 3-VL 
primers were then added (0.5 µM each) and the thermocycler was run for 15 cycles of 1 min 
at 96oC, 1 min at 53oC, 1 min at 72oC, and 1 cycle of 10 min at 72oC.  The resulting scFv 
DNA insert was purified and quantitated as above. 
 
5.2.3.2  Plasmid Construction 
 The purified scFv SOE PCR product and the pCTCON yeast display plasmid [Graff, 
2002] (a derivative of the pCT302 plasmid [Boder and Wittrup, 1997] with a BamHI site 
added 5 to the c-myc sequence) were digested with BamHI and NheI restriction enzymes for 
more than 2 hours at 37oC, according to the manufacturers instructions (New England 
Biolabs, Beverly, MA).  The restriction digest products were purified using the QIAquick® 
Kit, combined in an equimolar ratio (500 ng plasmid, 4 µg insert), and ligated using T4 DNA 
ligase (Stratagene) following the manufacturers instructions.  After incubating the ligation 
reaction mixture at room temperature for more than 2 hours, the reaction was heat 
deactivated at 65oC for 10 min.  The ligation products were used to transform XL1-Blue 
Supercompetent E. coli (Stratagene), following the manufacturers protocol, and plated on 
LB agar plates containing 50 mg/mL ampicillin.  Single colonies were each grown in 5 mL 
of LB containing 100 mg/L ampicillin at 37oC overnight and their plasmid clones were 
purified using the QIAprep® Spin Miniprep Kit.  A plasmid clone with the desired in-frame 
scFv insert was identified through DNA sequencing and labeled pEAG1.    
 
5.2.3.3  Yeast Transformation, Growth, and Induction 
EBY100 strain yeast cells [Boder and Wittrup, 1997] were transformed with pEAG1 
through electroporation, plated onto SD-CAA agar plates (7 g/L yeast nitrogen base, 5.4 g/L 
NaH2PO4, 8.6 g/L Na2HPO4, 5.0 g/L casamino acids, 20 g/L dextrose, Trp and Ura deficient) 
and incubated for 2.5 days at 30oC.  Cells originating from a single colony were grown in 5 
mL of SD-CAA media (7 g/L yeast nitrogen base, 2.7 g/L NaH2PO4, 5.0 g/L Na2HPO4, 5.0 
g/L casamino acids, 20 g/L dextrose) at 30oC on an orbital shaker for about 16 hours (OD600 
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= 4.0).  A volume of the yeast suspension containing 5x107 cells (OD600=1 represents 1x107 
cells/mL [Boder and Wittrup, 2000]) was centrifuged, re-suspended in 5 mL of SG-CAA 
induction media (same as SD-CAA, but substituting galactose for dextrose), and incubated at 
22oC on an orbital shaker for approximately 20 hours.   
 
5.2.3.4  Yeast Labeling 
The labeling of the yeast cells for FACS analysis was performed in a fashion similar 
to that previously described [VanAntwerp and Wittrup, 2000].  Each of a series of 1.5 mL 
centrifuge tubes were loaded with 1x106 EBY100 cells (transformed with pEAG1 and 
induced with galactose).  The tubes were centrifuged and the yeast pellets were washed with 
500 µL of PBS/BSA (PBS 7.4 with 0.1% bovine serum albumin added as a carrier).  Murine 
anti-HA tag antibody (12Ca5 MAb, Roche, Basel, Switzerland) and biotinylated recombinant 
human β2m were used as primary labeling agents at concentrations of 2 µg/mL and 1x10-11
1x10-6 M, respectively.  The primary labeling of each tube was carried out in 1.0 mL of 
PBS/BSA at room temperature on a rocker for 30 minutes.  The cells were spun down and 
washed as above with ice-chilled PBS/BSA.  Secondary labeling was conducted in 100 µL of 
PBS/BSA on ice for 15 minutes, using 40 µL/mL each of streptavidin-phycoerythrin 
(PharMingen, San Diego, CA) and FITC-conjugated anti-mouse IgG (Sigma, St. Louis, MO).  
The cells were centrifuged at 4oC and washed quickly with 500 µL of ice-chilled PBS/BSA.  
The labeled cell pellets were stored on ice and protected from light until FACS analysis. 
Four additional yeast pellets were labeled for FACS analysis, which served as 
controls.  The labeling was performed as described above, except that:  (1) the primary labels 
were omitted; (2) biotinylated recombinant human β2m and streptavidin-phycoerythrin were 
omitted; (3) the murine anti-HA tag antibody and FITC-conjugated anti-mouse IgG were 
omitted, (4) un-biotinylated recombinant human β2m was added in 100-fold molar excess to 
competitively inhibit the  biotinylated β2m. 
 
5.2.3.5  FACS Analysis 
The labeled yeast cell pellets were each resuspended in approximately 1.0 mL of 
PBS/BSA and analyzed with an Epics® XL FACS (fluorescence activated cell sorter; 
Beckman Coulter, Fullerton, CA) in a fashion similar to those previously described [Boder 
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and Wittrup, 2000; VanAntwerp and Wittrup, 2000].  Samples were gated by light scattering 
and then by FITC signal in order to avoid consideration of particles other than un-clustered 
scFv-displaying yeast cells.  The mean phycoerythrin (PE) signal for more than 2x104 scFv-
displaying cells labeled with each β2m concentration was recorded.  SPHEROTM Rainbow 
Calibration Particles (3.0-3.4 µm, Spherotech, Libertyville, IL) with six different known 
densities of surface-immobilized FITC were also analyzed (>1x103 counted at each density) 
to allow for the correlation of the mean FITC signal per cell to the mean number of scFv 
fragments displayed by each cell. 
 
5.2.3.6  Mathematical Modeling 
Assuming a monovalent antibody-antigen binding interaction, the antibody-antigen 
equilibrium dissociation constant, KD, is defined by Equation 5.1   
  2
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Here [scFv]eq, [β2m]eq, and [scFv*β2m]eq are the equilibrium concentrations (mole per L of 
cell suspension during primary labeling) of dissociated antibody fragment, dissociated 
antigen (β2m), and scFv fragment-antigen complex, respectively.   
Assuming that the binding of β2m by the scFv fragment is the only reaction 
consuming the dissociated species, [scFv]eq and [β2m]eq can be expressed in terms of other 
variables as described by Equations 5.2 and 5.3. 
  0 2 0 0 2[ ] [ ] [ * ] [ ] [ * ]eq eq eqscFv scFv scFv m P Y scFv mβ β= − = −  [5.2] 
  2 2 0 2[ ] [ ] [ * ]eq eqm m scFv mβ β β= −  [5.3] 
Here [scFv]0, [β2m]0, and [Y]0 are the initial molar concentrations of dissociated antibody 
fragment, β2m, and yeast cells during the primary labeling step and P0 is the mean number of 
scFv fragments displayed per cell (mole-scFv/mole-yeast).  The value of P0 was 
independently determined from the mean FITC signal and the calibration curve obtained 
from the FACS analysis of the SPHEROTM standards.   
The mean PE signal of the scFv-displaying population, F, is assumed to be a linear 
function of [scFv*β2m]eq as described by Equation 5.4, where C1 and C2 are empirical 
constants.   
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  1 2 2[ * ]eqF c scFv m cβ= +  [5.4] 
 Equations 5.1-5.4 can be combined and rearranged to yield Equation 5.5, which was 
used to regress the values of KD, c1, and c2 from each set of F vs. [β2m]0 data .   
 ( ) ( )21 2 0 0 0 2 0 0 0 0 0 2 0 2[ ] [ ] [ ] [ ] 4 [ ] [ ]2 D D
cF K m P Y K m P Y P Y m cβ β β = + + − + + − +     [5.5] 
 
5.2.4  Secretion of scFv fragment by yeast 
A His6-tag and a cysteine residue were added to the C-terminus of the secreted 
version of the BBM.1 scFv fragment to facilitate its purification and subsequent 
immobilization.  This location was chosen to minimize the interference of the purification tag 
and the immobilization bond with the β2m-binding site.  It was deemed necessary to remove 
the Lys-Arg sequence near the C-terminus of the VL gene because it is known to be cleaved 
by the Kex2 protease within the trans-Golgi network of Saccharomyces cerevisiae [Bevan et 
al., 1998; Rockwell and Fuller, 1998].   
 
5.2.4.1  Plasmid Construction 
The Lys-Arg sequence in the VL was removed by changing the Arg residue to Asn.  
This was achieved through PCR (50 µL reaction volume) with the 5-VH and 3-Lys-Asn 
primers (Figure 5.2, 0.25 µM each) and the pEAG1 plasmid (1 µL).  Cloned Pfu DNA 
polymerase and Cloned Pfu Reaction Buffer were used to carry out the reaction, following 
the manufacturers instructions.  The thermocycler was run for 1 cycle of 1 min at 98oC, 28 
cycles of 1 min at 98oC, 2 min at 72oC, and 1 cycle of 10 min at 72oC.  The resulting scFv 
PCR product was ligated into the pCT302 plasmid essentially as described for the 
construction of the pEAG1 plasmid, except that a 2:1 molar ratio of scFv insert to plasmid 
DNA was used during the ligation reaction.  A plasmid clone with the desired scFv insert, 
pEAG2, was obtained from the ligation reaction products in the same manner as pEAG1. 
The Kex2 protease resistant form of the BBM.1 scFv insert was amplified from the 
pEAG2 plasmid through PCR with the 5-VH and 3-His6-Cys primers (Figure 5.2).  The 
PCR was performed as described for the creation of pEAG2, except that the thermocycler 
was run for 1 cycle of 1 min at 98oC, 28 cycles of 1 min at 98oC, 1 min at 55oC, 1 min at 
72oC and 1 cycle of 10 min at 72oC.  The resulting scFv insert was ligated into the secretion 
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plasmid pRS-GALTwt [Shusta et al., 1999] in frame with the synthetic pre pro signaling 
sequence [Clements et al., 1991], under control of the GAL1,10 promoter.  The ligation 
protocol was essentially that described for the construction of the pEAG1 from pCTCON, 
except that the BamHI restriction enzyme was replaced with XhoI (New England Biolabs) 
and a 4:1 molar ratio of scFv insert to plasmid DNA was used.  A secretion plasmid clone 
with the desired scFv insert, pEAG3, was obtained from the ligation reaction products in the 
same manner as pEAG1 and pEAG2. 
 
5.2.4.2  Yeast Transformation, Growth, and Induction  
 YVH10 yeast, a protein disulfide isomerase overexpressing strain of Saccharomyces 
cerevisiae [Robinson et al., 1994], were transformed with pEAG3 and pRS314 (to add Trp- 
resistance to allow selection on Trp deficient media) [Sikorski and Hieter, 1989] using the 
lithium acetate/single-stranded carrier DNA/polyethylene glycol method [Agatep et al., 
1998].  Cells were plated onto selective SD-SCAA plates (6.7 g/L yeast nitrogen base, 7.5 
g/L NaH2PO4, 5.4 g/L Na2HPO4, 20 g/L dextrose, 15 g/L agar, 182 g/L sorbitol, and 
synthetic casamino acids:  40 mg/L adenine sulfate, 140 mg/L His, 190 mg/L Arg, 108 mg/L 
Met, 52 mg/L Tyr, 290 mg/L Ile, 440 mg/L Lys, 200 mg/L Phe, 1260 mg/L Glu, 400 mg/L 
Asp, 380 mg/L Val, 220 mg/L Thr, 130 mg/L Gly, deficient in Leu, Trp, and Ura) and 
incubated at 30oC for 3 days. 
Expansion of the transformed YVH10 cells was initiated by inoculating 50 mL of 
SD-SCAA liquid media (same as SC-SCAA plates, but with agar and sorbitol omitted) with 
cells originating from a single colony.  After incubating the starter culture on an orbital 
shaker at 30oC overnight (OD600 = 3.6), 30 mL of the starter culture was used to inoculate 6 L 
of SD-SCAA.  Each liter of SD-SCAA was placed into a 2.5 L fully baffled Tunair flask 
(Shelton Scientific, Shelton, CT) and incubated at 30oC for 1 day (OD600 = 6.8).  The yeast 
cells were then centrifuged and resuspended in 6 L of YPG induction media (10 g/L yeast 
extract, 20 g/L peptone, 20 g/L galactose) with 100 units/mL penicillin and 0.1 g/L 
streptomycin added to inhibit bacterial contamination.   Each liter of YPG was placed in a 2 
L, smooth-bottomed Erlenmeyer flask and incubated at room temperature (approximately 
22oC) for about 3 days (OD600 = 17.4).  The cell suspension was then centrifuged and the 
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supernatant was 0.2 µm filtered and concentrated to an approximate volume of 400 mL using 
a 10 kD Prep/Scale-TFFTM regenerated cellulose membrane (Millipore, Bedford, MA).   
 
5.2.4.3  Protein Purification 
The His6-tagged scFv fragment was purified from the concentrated cell culture 
supernatant via nickel affinity chromatography, for which PBS 8.0 (phosphate buffered 
saline, pH 8.0:  50 mM phosphate, 300 mM sodium chloride) was used with varying 
imidazole concentrations.  To remove metal contaminants, 5 mM sodium 
ethylenediaminetetraacetic acid (EDTA) was added to the concentrated culture supernatant, 
which was placed in a 400 mL stirred ultrafiltration cell with a 10 kD YM10 regenerated 
cellulose disk membrane (Millipore).  The cell was subsequently flushed with 2.8 L of PBS 
8.0 to facilitate buffer exchange.  To minimize the binding of un-tagged protein, 10 mM 
imidazole was added and the protein was bound to a 5 mL column of Ni-NTA agarose gel 
beads (Qiagen).  The resin was washed with 60 mL of 20 mM imidazole and eluted with 30 
mL of 250 mM imidazole.  The eluted protein was further purified by size-exclusion 
chromatography using Superose® 12 prep grade resin (Amersham Biosciences, Uppsala, 
Sweden) eluted with PBS 7.4.  The desired fractions were pooled and the concentration of 
scFv was measured by reading the absorbance at 280 nm, using a molar extinction coefficient 
of 51,130 L/mol cm-1 and a molecular weight of 29,032 g/mole.  These values were 
calculated from the amino acid sequence and the formula reported by Pace and co-workers 
[Pace et al., 1995].     
 
5.2.5  Immunoadsorbent based on scFv fragment 
5.2.5.1  Protein Immobilization 
Immediately prior to immobilization, the purified scFv fragment was reduced with 
Immobilized TCEP (Tris[2-carboxyethyl] phosphine hydrochloride]) Disulfide Reducing Gel 
(Pierce, Rockford, IL).  The reaction was performed for one hour at room temperature on a 
rocker in 3.5 mL of PBS 7.2 (phosphate buffered saline, pH 7.2:  100 mM PO4, 150 mM 
NaCl) containing 15 mM EDTA, 33% TCEP gel by volume, and 2.0 mg/mL scFv fragment.  
During the same hour, lysine Sepharose® 4B (Amersham Biotech) was activated with 
sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC, Pierce).  
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Sulfo-SMCC is a heterobifunctional cross-linking agent that reacts with sulfhydryl and 
primary amine groups.  This reaction was also performed for one hour at room temperature 
on a rocker, but in 4.5 mL of 150 mM sodium bicarbonate buffer (pH 8.8) containing 1.8 
mg/mL Sulfo-SMCC and 22% swollen lysine Sepharose® 4B gel by volume.   
Following the one-hour incubation, the activated lysine gel was rinsed (several times, 
totaling 30 volumes) and re-suspend with ice-cold PBS 7.2.  Immediately thereafter, the 
reduced scFv fragment was removed from the TCEP gel by centrifuging it in a Micro Bio-
Spin® (Bio-Rad, Hercules, CA) column.  The TCEP gel was rinsed with 1.0 mL of PBS 7.2 
to improve the recovery of the scFv fragment.  The scFv fragment immobilization reaction 
was performed for 24 hours on a rocker at 4oC in 4.0 mL PBS 7.2 containing 4.4 mg scFv 
fragment and 0.45 mL Sulfo-SMCC activated gel (settled bed volume).  The number free 
thiol groups per scFv fragment molecule, before and after contact with the TCEP gel, was 
measured using the Thiol and Sulfide Quantitation kit obtained from Molecular Probes.  The 
kit instructions were followed except that the degassing performed by argon bubbling instead 
of using vacuum desiccator. 
The following day, the soluble scFv fragment was removed from the gel by 
centrifuging it in a Micro Bio-Spin column and the gel was rinsed 4 times with 2.0 mL of 
PBS 7.2.  The gel was re-suspended in 2.0 mL PBS 7.2, containing 1 mM L-cysteine as a 
quenching agent, and incubated overnight at 4oC on a rocker.  After quenching, the gel was 
centrifuged, rinsed four times as before, and resuspended in PBS 7.4.  Equal volumes of the 
reduced scFv fragment, the quenching buffer, and the eight rinses were assayed for protein 
by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis).  A control 
matrix was prepared by immobilizing L-cysteine onto lysine Sepharose® 4B gel following 
the above protocol, omitting the scFv-protein.   
 
5.2.5.2  Characterization 
 Alexa Fluor® 488-labeled recombinant human β2m (β2m-AF488, see Section 5.2.1) 
was used to determine the β2m-adsorption capacity of the agarose-immobilized scFv 
antibody fragment and control matrix.  A series of 0.5 mL centrifuge tubes were each loaded 
with 100 µL of 10% gel suspension in FCS/PBS (75% fetal calf serum, 25% PBS 7.4 by 
volume), a saturating quantity of β2m-AF488 (16, 12 or 10 µg; 0.96 mg/mL stock), and 
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sufficient FCS/PBS to bring the total volume to 0.400 mL.  The tubes were equilibrated at 
37oC for 1 hour on a rocker and then centrifuged.  From each tube, three 100 µL volumes of 
supernatant were loaded into individual wells of a 96-well plate, which was also loaded with 
calibration standards (0, 10, 20, 30, 40, and 50 mg/L of β2m-AF488 in FCS/PBS).  The plate 
was read by a Mithras LB 940 plate reader (Berthold Technologies, Bad Wildbad, Germany), 
using excitation and emission wavelengths of 485 and 535 nm, respectively.  A linear 
calibration curve was generated and was used to determine the β2m-AF488 concentrations of 
the experimental samples.  The β2m-adsorption capacity of the agarose-immobilized scFv 
antibody fragment was calculated from this data, using Equation 5.6. 
  ( )0totals eq
gel
V C C
V
ρ′ = −  [5.6] 
Here ρ′s is the adsorption site density (mg β2m per mL of settled gel), Vtotal is the total volume 
of each tube (mL), Vgel is the settled-volume of the gel (µL), C0 is the initial β2m 
concentration (mg/L), and Ceq is the concentration of desorbed β2m at equilibrium (mg/L).  
For regeneration, the labeled gel was recovered from the centrifuge tubes, placed in a 
Micro Bio-Spin® column, and centrifuged.  The immunoadsorptive media was regenerated 
by rinsing it four times with 2.0 mL of stripping buffer (300 mM glycine, pH 2.8).   The 
regenerated media was rinsed four times with 2.0 mL of PBS 7.4, and then rinsed once and 
resuspended with FCS/PBS to make a 10% suspension.  The adsorption capacity of the 
regenerated immunoadsorptive media was measured as above. 
 The affinity of the regenerated immunoadsorptive media for β2m was assessed by 
following the protocol used to determine the adsorption capacity, except that each tube was 
loaded with twice the amount of gel along with a sub-saturating quantity of β2m-AF488 (6 
µg).  The calibration standards also spanned a lower concentration range (0, 0.5, 1.0, 2.5, 5.0, 
10, 15 mg/mL). 
Leaching of the scFv fragment by the stripping buffer was assayed through Western 
blotting.  Diluting it with 13 mL of 100 mM sodium phosphate, 1 mM EDTA, pH 8.0, 
neutralized each 2.0 mL volume of stripping buffer.  Equal volume samples of the 
neutralized stripping buffer and similarly diluted scFv from the immobilization reaction were 
run on SDS-PAGE with 5% 2-mercaptoethanol added to the sample buffer as a reducing 
agent.  A PVDF (polyvinylidene difluoride) membrane was used for blotting, which was 
 90 
labeled with Anti-His HRP conjugate (using the included Anti-His HRP conjugate blocking 
buffer) following the manufacturers instructions (Qiagen).  However, PBS 7.4 was used 
instead of Tris buffered saline.  Colorimetric detection was performed using the Opti-4CNTM 
substrate kit (Bio-Rad), again following manufacturers instructions. 
 
5.2.6  Statistical Analysis 
Measured quantities are reported as the mean ± the standard error of the mean (SEM), 
except for the scFv immobilization density and the mass ratio of adsorbed β2m to 
immobilized antibody, for which the error estimates correspond to the accuracy of the gel 
volume measurement.  The significance of the difference between two means was tested by 
ANOVA (analysis of variance) using a two-tailed p value of 0.05.  Regressions were 
performed by minimizing the summed square error (SSE). 
 
5.3  RESULTS 
5.3.1  Cloning of VH and VL genes 
As resolved by agarose gel electrophoresis, one combination of the Ig-Prime kit 
heavy chain primers (MuIgVH5-D and MuIgVH3-2) and three combinations of the light 
chain primers (MuIgκVL5-B, MuIgκVL5-C, and MuIgκVL5-E, each with MuIgκVL3-1) 
yielded RT-PCR products that were characteristic of VH and VL genes (approximately 400 
base pairs in length).  The DNA sequences of two of the VL RT-PCR products (MuIgκVL5-
B and MuIgκVL5-C) were found to match the aberrant light chain sequence listed in the Ig-
Prime kit instructions [Carroll et al., 1988] and were discarded.  The sequences of the 
remaining VH and VL genes (Figure 5.3) were translated and compared to the peptide 
sequencing results of the protein A-purified BBM.1 antibody.   
Three different peptide chains were detected by N-terminal degradation, where only 
two were expected for a pure monoclonal.  The signal for one of the peptide chains was too 
weak to determine its sequence with a high level of confidence, while the two predominant 
peptide chains were found in approximately equal proportions.  The sequence of the MOPC-
21 κ light chain was used to infer the sequence of the second peptide chain in the BBM.1 
antibody sample.  This peptide sequence matched the cloned VH sequence, but did not match 
that of the MOPC-21 heavy chain [Milstein et al., 1974].   Meanwhile, the sequence of the 
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cloned VL gene did not match the sequence of the MOPC-21 κ light chain.  These findings 
suggested that the cloned VH and VL genes belonged to the anti-β2m antibody secreted by the 
BBM.1 hybridoma.   
 
5.3.2  Display of scFv fragment by yeast 
The ability of the cloned VH and VL genes to bind β2m was confirmed by expressing 
them as a scFv fragment in a yeast display format.  The addition of 100-fold molar excess un-
biotinylated β2m effectively inhibited the binding of the biotinylated β2m, while the average 
number of scFv fragments displayed by the pEAG1-transformed yeast was 2.x104 ± 0.3x104 
mole-scFv/mole-yeast (P0).  The three FACS titration curves that were used to determine the 
value of the scFv-β2m dissociation equilibrium constant are summarized by Figure 5.4 (KD = 
0.7 ± 0.3 nM = 0.008 ± 0.004 mg-β2m /L).  Based on these results, it was concluded that the 
cloned VH and VL genes belong to the anti-β2m antibody produced by the BBM.1 cell line.   
 
5.3.3  Secretion of scFv fragment by yeast 
 Figure 5.5 gives the sequence of the secreted scFv fragment, while Figure 5.6 
demonstrates the purity of the scFv fragment after purification by nickel affinity 
chromatography.  One minor peak and two major peaks were eluted from the size-exclusion 
column (as resolved by monitoring the absorbance of at 280 nm).  The minor peak 
corresponded to the exclusion-limit of the resin, while the two major peaks (approximately 
the same size) corresponded to the molecular weights of the scFv fragment and its dimer.  
The fractions from the two major peaks were pooled to improve the yield of scFv fragment 
preparation and used to produce the immunoadsorptive media.  The yield of purified scFv 
fragment per unit volume of culture was 1.5 mg/L. 
 
5.3.4  Immunoadsorbent based on scFv fragment 
The TCEP reducing gel increased the molar ratio of free thiol groups to scFv 
fragments from less than 0.1% to 50%.  At the end of the immobilization reaction, 25% of 
the total, or 50% of the reduced scFv fragment, had bound to the Sulfo-SMCC-activated gel.  
This corresponds to an immobilization density of 2.4±0.2 mg-scFv/mL-settled-gel.  No 
leaching of the scFv fragment from the immunoadsorbent was detected in the PBS rinses 
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(SDS-PAGE), cysteine quenching buffer (SDS-PAGE), or in the neutralized stripping buffer 
(Western blot).  
 Initial β2m Concentration, C0 [mg/L] 
 40 30 25 Mean Significance 
Before Regeneration (N = 3) 
[mg-β2m/mL-settled-gel]  0.33 ± 0.04
 0.41 ± 0.01 0.48 ± 0.05 0.40 ± 0.04 p > 0.2 
After Regeneration (N = 5) 
[mg-β2m/mL-settled-gel]  0.41 ± 0.02 0.44 ± 0.02 0.43 ± 0.01 0.43 ± 0.01 p > 0.6 
Mean [mg-β2m/mL-settled-gel]    0.41 ± 0.01  
Significance    p > 0.2  
 
The observed β2m-adsorption site density (ρ′s) did not significantly depend on the 
β2m-concentration under saturating conditions, nor did it significantly change after one round 
of regeneration (Table 5.1).  The average measured value of ρ′s was 0.41 ± 0.01 mg-β2m/mL-
settled-gel, which corresponds to a binding activity of 42% (molar ratio of adsorbed β2m to 
immobilized scFv fragment) for the immobilized scFv fragment.  Under sub-saturating 
conditions (C0 = 15 mg/mL), the regenerated immunoadsorbent possessed sufficient affinity 
to bring the concentration down to Ceq = 1.0 ± 0.1 mg/L (N = 5).   
                                                 
* Various initial concentrations (C0) of β2m-AF488 were equilibrated with 10 µL volumes of the 
immunoadsorptive media (Vgel) in 0.400 mL of FCS/PBS (Vtotal) at 37oC for 1 hour.  The equilibrium 
concentration of desorbed β2m-AF488 (Ceq) was measured and used to calculate the β2m-adsorption site density 
(ρ′s) using Equation 5.6.  These experiments were conducted on the immunoadsorptive media before and after 
regeneration with 0.3 M glycine, pH 2.8. 
 N = 2 
Table 5.1  β2m-Adsorption Site Density of the Immunoadsorptive Media (ρ′s).* 
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5.4  DISCUSSION 
 The removal of β2m from human blood plasma has previously been investigated with 
immunoadsorbents consisting of whole anti-β2m antibodies immobilized onto porous beads 
[Mogi et al., 1989; Nakano et al., 1991; Vallar et al., 1995; Shabunina et al., 2001].  These 
small-scale affinity chromatography experiments have demonstrated that an 
immunoadsorbent can remove β2m from human plasma with an affinity that has not been 
achieved with hydrophobic interaction-based adsorbents [Furuyoshi et al., 1998; Davankov 
et al., 2000].  Furthermore, these antibody-based adsorbents were found to be highly specific 
for β2m, while the specificity of hydrophobic interaction-based adsorbents continues to be a 
concern [Tsuchida et al., 1998; Reiter et al., 2002].  To date, perhaps the most promising 
anti-β2m immunoadsorbent has been reported by Vallar and co-workers [Vallar et al., 1995], 
which consisted of monoclonal antibodies immobilized onto Sepharose® CL-4B gel beads.  
This adsorbent was highly regenerable and possessed a β2m-adsorption site density (0.9 mg-
β2m/mL-settled-gel) that is expected to be sufficient, but not optimal for actual clinical 
application (i.e. 350 mL settled volume of adsorbent required to remove 315 mg of β2m).   
While the results of these preliminary investigations are encouraging, the challenge of 
removing β2m from whole blood in a single extracorporeal device has not been addressed 
until recently (Chapter 2, [Ameer et al., 2001]).  More specifically, low concentrations of 
β2m (3.2 mg/L) were removed from whole human blood in vitro at a therapeutically relevant 
flowrate (200 mL-blood/min) using a novel, plasmapheretic extracorporeal device (the 
VFPR) and an immunoadsorbent based on whole BBM.1 antibodies.  The concentration of 
β2m that was cleared by the VFPR device was limited by a low β2m-adsorption site density 
(ρ′s = 0.030 ± 0.002 mg-β2m/mL-settled-gel), which was caused by the low molar binding 
activity of the immobilized BBM.1 antibody (only 6% of the immobilized antibody bound 
β2m).  Nevertheless, the immobilized whole antibodies (BBM.1) that retained binding 
activity demonstrated a high affinity for β2m (KD = 0.1 ± 0.1 mg/L) as well as the ability to 
be regenerated repeatedly (>10x) without a detectable loss of binding activity.  At the time, it 
was hypothesized that the low β2m-adsorption site density was either caused by the excessive 
deactivation of the monoclonal antibody by the immobilization chemistry (cyanogen bromide 
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activation of agarose) and/or the expression of an additional, unwanted immunoglobulin 
chain (impurity) by the hybridoma cell line.   
Research into the origin of the BBM.1 antibody-producing hybridoma cell line (HB-
28) has revealed that it was created using the X63-Ag8 myeloma [Brodsky et al., 1979], 
which has been shown to secrete the MOPC-21 κ light and IgG1 heavy chains [Milstein et al., 
1974; Kohler and Milstein, 1975].  In light of this fact, protein-A purified BBM.1 antibody 
was partially sequenced through N-terminal degradation.  The results suggest that the protein 
sample primarily consisted of the MOPC-21 light chain and an IgG heavy chain other than 
the MOPC-21 IgG1 chain (presumably the anti-β2m heavy chain), with a trace amount 
(<10%) of a third peptide chain (presumably the anti-β2m light chain).  The apparent absence 
of MOPC-21 IgG1 in the protein sample can be explained by the fact that protein A is known 
to bind to IgG2b with a higher affinity than IgG1 [Ladisch, 2001] and that the BBM.1 
antibody has been classified as IgG2b [Brodsky et al., 1979].  
 The optimization of an immunoadsorbent for the extracorporeal removal of β2m will 
require the maximization of the β2m-adsorption site density to minimize the required volume 
of immunoadsorbent.  The volume of immunoadsorbent contained within the extracorporeal 
device is an important parameter for the optimization of biocompatibility, as it is proportional 
to the amount of blood plasma retained during therapeutic operation.  One strategy for 
achieving higher β2m-adsorption site densities is to use scFv antibody fragments as 
immunoadsorption ligands instead of significantly larger whole antibodies (1 mg of scFv 
fragment can bind 0.4 mg of β2m, whereas 1 mg of whole antibody can only bind 0.16 mg of 
β2m).  Another advantage of scFv fragments over whole antibodies is their ability to be 
expressed by microbial vectors.  This makes scFv fragments amenable to in vitro evolution in 
a convenient yeast display format and provides more options for process optimization, 
potentially resulting in a significant reduction in production cost.  ScFv fragments are also 
genetically defined, which offers the opportunity to eliminate the expression of unwanted 
peptide chains by the source hybridoma cell line. 
Motivated by the potential advantages of scFv fragments, the desirable affinity and 
regeneration capacity of BBM.1, and the apparent MOPC-21 κ light chain contamination, an 
immunoadsorbent for the removal of β2m was created that is based on BBM.1 scFv 
fragments.  The BBM.1 scFv was first expressed in a yeast display format to facilitate the 
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characterization of its phenotype and to enable the engineering of its properties (i.e. stability 
and/or regeneration capacity under various conditions) through in vitro evolution, if it is 
desired in the future. 
The binding affinity of the yeast-displayed scFv fragment for β2m was quantitated by 
FACS analysis.  The measured value of KD (0.7 ± 0.3 nM = 0.008 ± 0.004 mg/L) is in 
agreement with that previously reported for the agarose-immobilized whole BBM.1 antibody 
(0.1 ± 0.1 mg/L) (Chapter 4, [Grovender et al., 2002]).  This result is noteworthy from an 
antibody engineering perspective, because the conversion of a whole antibody to a wild-type 
scFv fragment can result in a significant decrease in affinity [Maynard et al., 2002].  
Furthermore, our reported value for KD is well below the β2m concentration range expected 
in the blood plasma of healthy individuals (1.0-3.0 mg/L) [Floege and Ketteler, 2001].  
Hence, the yeast-displayed wild-type BBM.1 scFv fragment possesses an affinity for 
recombinant human β2m that is optimal for the clinical treatment of DRA through 
extracorporeal immunoadsorption.  
Given the encouraging binding affinity of the yeast-displayed antibody fragment, the 
scFv gene* was expressed by a yeast secretion vector.  The selected protein expression and 
purification methods produced enough of the scFv fragment so that a small volume of a 
model scFv immunoadsorbent could be produced for investigational purposes.   The molar 
binding activity (42%) and the β2m-adsorption site density (ρ′s = 0.41 ± 0.01 mg-β2m/mL-
settled-gel) of the scFv-based adsorbent are significantly greater than those measured for the 
whole BBM.1 antibody-based adsorbent (molar binding activity of 6%, ρ′s = 0.030 ± 0.002 
mg-β2m/mL-settled-gel).  This improvement can be attributed to the elimination of the 
production of the MOPC-21 light chain by the cloning procedure.  Hence, this work 
demonstrates how the creation of a wild-type scFv fragment from an existing hybridoma cell 
line can be used to separate desired antibody genes from contaminating ones.  Under 
saturating conditions (Ceq >> KD), the mass ratio of adsorbed β2m to immobilized antibody 
(0.17 ± 0.02 mg-β2m/mg-scFv) is roughly equivalent to the theoretical limit for 100% active, 
bivalent whole IgG antibody (0.16 mg-β2m/mg-antibody) and 70% higher than that actually 
achieved by Vallar and co-workers (0.1 mg-β2m/mg-antibody) [Vallar et al., 1995].  
                                                 
* A Kex2 protease-resistant version. 
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Shabunina and co-workers [Shabunina et al., 2001] have immobilized whole, polyclonal anti-
β2m antibodies onto Sepharose® CL-4B at densities that range from 2 to 16 mg/mL-settled-
gel.  Over this range the mass ratio of adsorbed β2m to immobilized antibody remained 
constant (0.04 mg-β2m/mg-antibody).  If this immobilization density can be achieved for the 
BBM.1 scFv while maintaining a molar binding activity of 42%, a new immunoadsorbent 
with a β2m-adsorption site density of 2.7 mg-β2m/mL-settled-gel could theoretically be 
produced.  This would represent a 3-fold increase over the β2m-adsorption site density 
reported by Vallar and co-workers [Vallar et al., 1995], which is the highest reliable value 
reported in the literature.*   
This is the first time that a scFv-based adsorbent for the extracorporeal removal of 
β2m has been reported.  Under saturating conditions, this new type of immunoadsorbent 
binds a mass ratio of adsorbed β2m to immobilized antibody that is above the theoretical 
limit obtainable with whole antibodies.  Future work will involve the optimization of the 
scFv fragment expression, purification, and immobilization methods.  A large volume (100-
200 mL) of this scFv-based immunoadsorbent will be produced and used within a VFPR 
device to remove pathologic levels (20-70 mg/L [Gejyo et al., 1986; Koch, 1992]) of β2m 
from human blood. We expect that the immobilization density of the scFv fragment can be 
increased sufficiently such that, when combined with the high mass ratio of adsorbed β2m to 
immobilized antibody, a β2m-adsorption site density can be achieved that is significantly 
greater than the highest reported to date (ρ′s = 0.9 mg-β2m/mL-settled-gel [Vallar et al., 
1995]).  This increase in the β2m-adsorption site density should translate into a proportionate 
decrease in the volume of adsorbent needed for extracorporeal therapy and the blood plasma 
retained, thereby improving the biocompatibility of the device. 
                                                 
* Mogi and co-workers [Mogi et al., 1989] have reported a β2m-adsorption site density of 4.3 mg/mL.  
However, this value is not reliable because their reported antibody immobilization density (18.8 mg-
antibody/mL-gel) corresponds to a mass ratio of adsorbed β2m to immobilized antibody (0.23 mg-β2m/mg-
antibody) that is well above the theoretical limit (0.16 mg-β2m/mg-antibody).   
 
 To the best knowledge of the author and Thesis Advisory Committee. 
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Figure 5.1 Schematic diagram of yeast display.  (A) The gene encoding the scFv 
fragment of interest is cloned into the pCT302 plasmid (or derivative) in frame with the 
Aga2p mating protein, which is under control of the GAL1,10 promoter.  The EBY100 
strain of Saccharomyces cerevisiae possesses a single, integrated copy of the Aga1p gene 
which is also under control of the GAL1,10 promoter.  Upon induction by galactose, 
EBY100 cells transformed with pCT302 co-express Aga1p and the Aga2p-scFv fusion.  
Aga1p is covalently bound to the cell wall and the Aga2p-scFv fusion.  (B) Anti-HA tag 
antibody, anti-c-myc tag antibody, and labeled antigen can be used to characterize the 
expression and activity of the scFv using a fluorescence-activate cell sorter (FACS).  
Objects are not drawn to scale. 
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5-VH: 
 
                /NheI    
  G ATC GAT CGA GCT AGC GAG GTT CAG CTG CAG CAG TC 
     I   D   R   A   S   E   V   Q   L   Q   Q 
                       |-> VH 
 
3-VH:         
 
 CC TCA GTC ACC GTC TCC TCA GGT GGT GGT GGT TCT GGT GGT GGT GGT TCT GGC 
     S   V   T   V   S   S   G   G   G   G   S   G   G   G   G   S   G    
                      VH <-|-> Linker  
 
GGC GGC GGC TCC 
 G   G   G   S 
                       
 
5-VL:        
 
GGC GGC GGC GGC TCC GGA GGA GGA GGA TCG GAC ATT CAG ATG ACC CAG 
 G   G   G   G   S   G   G   G   G   S   D   I   Q   M   T   Q 
                              Linker <-|-> VL 
 
3-VL:        
                                                /BamHI 
TTC GGA GGG GGG ACC AAG CTG GAA ATA AAA CGG GCT GGA TCC GAT CGA TCG ATC 
 F   G   G   G   T   K   L   E   I   K   R   A   G   S   D   R   S   I 
                                          VL <-| 
 
3-Lys-Asn:   
                                                    /BamHI 
TTC GGA GGG GGG ACC AAG CTG GAA ATA AAA AAC GCT GAT GGA TCC GAT CGA TCG 
 F   G   G   G   T   K   L   E   I   K   N   A   D   G   S   D   R   S    
                              VL <-|Lys-Asn| 
 
ATC 
 I 
 
3-His6-Cys:   
                                                                /XhoI 
CTT ATT TCT GAA GAG GAC TTG CAC CAC CAC CAC CAC CAC TGT TAG TGA CTC GAG 
 L   I   S   E   E   D   L   H   H   H   H   H   H   C  STP STP  L   E    
               C-myc-tag <-|->      His-tag      <-|Cys| Stop  | 
 
GAT CGA TCG 
 D   R   S 
Figure 5.2 Custom primers used for PCR.  The assembly of the scFv insert by SOE 
was performed using 5-VH, 3-VH, 5-VL and 3-VL.  The inserts for pEAG2 and pEAG3 
were made using 5-VH, 3-Arg-Asn and 3-His6-Cys.  The 3-VL-Arg-Asn also 
reintroduces the 110th amino acid in the BBM.1 VL gene, which was omitted from the 
3-VL primer.  The sequences of the 3 primers listed are the reverse compliment of those 
actually used. 
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VH: 
 
GAG GTT CAG CTG CAG CAG TCT GGG GCA GAG CTT GTG AAG CCA GGG GCC TCA  51 
 E   V   Q   L   Q   Q   S   G   A   E   L   V   K   P   G   A   S   17 
 
GTC AAG TTG TCC TGC ACA CCT TCT GGC TTC AAT GTT AAA GAC ACC TAT ATA 102 
 V   K   L   S   C   T   P   S   G   F   N   V   K   D   T   Y   I   34 
 
CAC TGG GTG AAA CAG AGG CCT AAA CAG GGC CTG GAG TGG ATT GGA AGG ATT 153 
 H   W   V   K   Q   R   P   K   Q   G   L   E   W   I   G   R   I   51 
 
GAT CCT TCG GAT GGT GAT ATT AAA TAT GAC CCG AAG TTC CAG GGC AAG GCC 204 
 D   P   S   D   G   D   I   K   Y   D   P   K   F   Q   G   K   A   68 
 
ACT ATA ACA GCA GAC ACA TCC TCC AAC ACA GTC TCC CTG CAG CTC AGC AGC 255 
 T   I   T   A   D   T   S   S   N   T   V   S   L   Q   L   S   S   85 
 
CTG ACA TCT GAG GAC ACC GCC GTC TAT TAC TGT GCT AGA TGG TTT GGT GAC 306 
 L   T   S   E   D   T   A   V   Y   Y   C   A   R   W   F   G   D  102 
 
TAC GGG GCT ATG AAC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC TCA 357 
 Y   G   A   M   N   Y   W   G   Q   G   T   S   V   T   V   S   S  119 
 
VL: 
 
GAC ATT CAG ATG ACC CAG TCT CCT GCC TCC CAG TCT GCA TCT CTG GGA GAA  51 
 D   I   Q   M   T   Q   S   P   A   S   Q   S   A   S   L   G   E   17 
 
AGT GTC ACC ATC ACA TGC CTG GCA AGT CAG ACC ATT GGT ACA TGG TTA GCT 102 
 S   V   T   I   T   C   L   A   S   Q   T   I   G   T   W   L   A   34 
 
TGG TAT CAG CAG AAA CCA GGG AAA TCT CCT CAG CTC CTG ATT TAT GCG GCA 153 
 W   Y   Q   Q   K   P   G   K   S   P   Q   L   L   I   Y   A   A   51 
 
ACC AGC TTG GCA GAT GGG GTC CCA TCA AGG TTC AGT GGT AGT GGA TCT GGC 204 
 T   S   L   A   D   G   V   P   S   R   F   S   G   S   G   S   G   68 
 
ACA AAA TTT TCT CTC AAG ATC AGG ACC CTA CAG GCT GAA GAT TTT GTA AGT 255 
 T   K   F   S   L   K   I   R   T   L   Q   A   E   D   F   V   S   85 
 
TAT TAC TGT CAA CAA CTT TAC AGT AAA CCG TAC ACG TTC GGA GGG GGG ACC 306 
 Y   Y   C   Q   Q   L   Y   S   K   P   Y   T   F   G   G   G   T  102 
 
AAG CTG GAA ATA AAA CGG GCT GAT                                     330 
 K   L   E   I   K   R   A   D                                      110 
 
 
Figure 5.3 VH and VL Genes Cloned from the BBM.1 Hybridoma. 
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Figure 5.4 Titration of BBM.1-scFv displaying yeast with fluorescent β2m.  Aliquots 
of EBY100 cells transformed with pEAG1 and displaying wild-type BBM.1-scFv 
fragment were labeled with various concentrations of biotinylated β2m.  Streptavidin-PE 
was used to label the adsorbed β2m.  The mean PE signal of the scFv-displaying 
population of each yeast aliquot was measured by a fluorescence-activated cell sorter 
(FACS).  Error bars represent standard error of the mean (SEM). 
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N-terminal Flanking Sequence:  
 
                /NheI   
GAA GCT CGG CCG GCT AGC GAG GTT CAG CTG CAG CAG TCT GGG GCA GAG  
 E   A   R   P   A   S   E   V   Q   L   Q   Q   S   G   A   E   
      Spacer <-|       |-> VH 
             
 
C-terminal Flanking Sequence:  
 
                        /BamHI                                           
GAA ATA AAA AAC GCT GAT GGA TCC GAA CAA AAG CTT ATT TCT GAA GAG GAC TTG 
 E   I   K   N   A   D   G   S   E   Q   K   L   I   S   E   E   D   L 
       |Lys-Asn|  VL <-|       |->             C-myc-tag            <-| 
 
CAC CAC CAC CAC CAC CAC TGT  
 H   H   H   H   H   H   C   
|->      His-tag     <-|Cys| 
 
 
 
 
 
Figure 5.5 The scFv fragment secreted by YVH10 yeast transformed with pEAG3.  The 
full sequences of the VH and VL genes are given by Figure 5.3. 
 
Figure 5.6 SDS-PAGE of the secreted BBM.1-scFv fragment after nickel affinity 
purification.  The reduced sample was treated with 5% betamercaptoethanol and boiled for 5 
minutes to dissociate the scFv dimer. 
ReducedNon-Reduced
ScFv Dimer
ScFv Monomer
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Chapter 6:  Afterword 
6.1  SUMMARY AND CONCLUSIONS 
The body of work presented in this thesis supports the feasibility of using an 
extracorporeal immunoadsorptive VFPR to specifically remove β2m from blood for the 
prevention and/or treatment of DRA (dialysis-related amyloidosis).  Furthermore, this blood 
detoxification technology platform could potentially be used to treat other diseases that are 
caused by circulating molecules that are otherwise difficult to remove (sepsis, liver failure, 
autoimmune disease, drug overdoses, and genetic disorders).  The biocompatibility and 
efficacy of the proposed therapy was evaluated with a model immunoadsorbent consisting of 
whole BBM.1 antibodies immobilized onto porous agarose gel beads (Chapter 2).  
Concurrently, a dynamic immunoadsorption model was developed for the VFPR that was 
based upon the independent characterization of the mass-transfer processes within the VFPR 
and the thermodynamic behavior of the model immunoadsorbent (Chapter 4).  The molar 
binding activity of the immobilized BBM.1 antibody was lower than expected (6%), but its 
β2m-adsorption site density (0.030 ± 0.002 mg-β2m/mL-settled-gel) was sufficient for 
preliminary research.  Hence, this model immunoadsorbent was used in a VFPR prototype to 
remove β2m from donated bags of human blood in a closed-loop circuit at a clinically 
relevant flowrate (200 mL/min blood circulation rate).  Over a two-hour operating period, no 
significant change was detected in the complete blood count and the total mass of soluble 
blood protein.  Meanwhile, the plasma free hemoglobin increased at a rate deemed 
acceptable for hemodialysis [Ameer et al., 1999].  This preliminary safety data supports the 
feasibility of using an immunoadsorptive VFPR for the extracorporeal removal of β2m. 
The high-affinity of the proposed β2m removal system was demonstrated by the 
ability of the immunoadsorptive VFPR to bring the concentration of native donor baseline 
β2m (1.3 ± 0.1 mg/L) to a level that was below the detectable limit of the assay (0.1 mg/L).  
The immunoadsorbent was successfully regenerated and used to remove controlled amounts 
(3.2 ± 2 mg/L) of recombinant human β2m from the same donated bags of human blood.  The 
dynamics of β2m clearance from the blood bags was predicted by the mathematical 
immunoadsorption model, without using adjustable parameters.  The predicted and 
experimentally observed time-scales of β2m removal from the blood were in agreement with 
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that calculated by dividing the total cell-free blood path (445 mL) by the hemofiltration rate 
(50 mL-plasma/min).  This finding led to the conclusion that the mass-transfer processes 
within the active plasma compartment of the VFPR prototype were not rate-limiting.  
Furthermore, the process controlling the rate of β2m removal from the blood was the 
hemofiltration rate, which was on the order of the supply rate of β2m into the circulation 
(approximately 70 mL/min [Floege et al., 1991]).  Both of these mass-transfer processes are 
expected to be rate-controlling should this specific device design be used for the 
extracorporeal removal of β2m.    
The ideal extracorporeal β2m removal technology would detoxify blood at a rate that 
is much faster than the supply rate of β2m to the circulation.  In light of this, a new VFPR 
prototype with a 22% longer microporous membrane was constructed.  The macroscopic 
mixing patterns within this new prototype were characterized using the same experimental 
and mathematical methods that were used in the development of the dynamic 
immunoadsorption model (Chapter 3).  The compartmental macroscopic mixing model was 
able to describe the residence-time distribution data (r2 > 0.94) over the range of process 
conditions considered.  This suggests that the plasma flux across the microporous membrane 
was not a function of position, which was an assumption of the model derivation.  Therefore, 
the new VFPR prototype is expected to allow for a proportionate increase in the rate of β2m 
removal (hemofiltration rates of 70-85 mL-plasma/min). 
In order to reduce the hold-up and/or loss of valuable plasma proteins during 
extracorporeal therapy, the ideal immunoadsorbent for the removal of β2m should possess a 
high β2m-adsorption site density (>1 mg-β2m/mL-settled-gel).  ScFv antibody fragments 
should theoretically allow for higher effective β2m-adsorption site densities because they are 
smaller in size than whole antibodies.  This theoretical basis motivated the creation of the 
BBM.1 scFv fragment and a scFv-based immunoadsorbent for a feasibility study (Chapter 5).  
The molar binding activity (42%) and the β2m-adsorption site density (ρ′s = 0.41 ± 0.01 mg-
β2m/mL-settled-gel) of the scFv-based adsorbent were dramatically improved from that of 
the whole BBM.1 antibody-based adsorbent (described above).  This improvement was 
attributed to the elimination of the expression of a non-β2m-binding immunoglobulin chain 
by the cloning procedure.  Under saturating conditions, the mass ratio of adsorbed β2m to 
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immobilized antibody is roughly equivalent to the theoretical limit for 100% active, bivalent 
whole IgG antibody and 70% higher than the highest value reported in the literature for 
immobilized anti-β2m whole antibodies (0.1 mg-β2m/mg-antibody) [Vallar et al., 1995].   
 Whole anti-β2m antibodies have been immobilized onto agarose gel beads at densities 
ranging from 2 to 16 mg/mL-settled-gel, without a detectable decrease in the mass ratio of 
adsorbed β2m (under saturating conditions) to immobilized antibody [Shabunina et al., 
2001].  If this immobilization density can be achieved for the BBM.1 scFv fragment through 
the optimization of the immobilization process while maintaining a molar binding activity of 
42%, a new immunoadsorbent could be produced with a β2m-adsorption site density of 2.7 
mg-β2m/mL-settled-gel.  This would represent a 3-fold improvement over the highest β2m-
adsorption site density reported to date [Vallar et al., 1995].  The ability of this hypothetical 
adsorbent to remove β2m from whole blood was predicted using the VFPR 
immunoadsorption model (Chapter 4) and a set of input parameters (Table 6.1) 
corresponding to the large VFPR prototype (Chapter 3).  According to the model calculations 
(Figure 6.1), this immunoadsorptive VFPR should be able to reduce a pathologically elevated 
β2m concentration of 60 mg/L* to a level that is within normal the normal range of healthy 
individuals (1.0-3.0 mg/L [Floege and Ketteler, 2001]) over the 5-hour period.  This 
corresponds to 313 mg of β2m removed from the blood reservoir or twice the amount 
reported to be removed by the kidneys daily (150 mg [Vincent et al., 1980]). 
Increasing the adsorption site density of the immunoadsorbent should theoretically 
allow for a proportionate decrease in the volume of adsorbent required for extracorporeal 
therapy, thereby enhancing biocompatibility.  In existing direct hemoperfusion devices such 
as the Lixelle® [Furuyoshi et al., 1998] and Betasorb® [Ronco et al., 2001] columns, the 
rate of β2m removal is directly proportional to the volume of adsorbent contained within 
them.  This is due to the low surface area to volume ratio of the relatively large (>400 µm) 
adsorbent particles that are required for biocompatibility with whole blood for this 
application.  Therefore, a decrease in the adsorbent volume of these direct hemoperfusion 
columns would come at the expense of a proportionate decrease in the β2m removal rate.  
                                                 
* Plasma β2m concentrations of chronic hemodialysis patients typically range 20-70 mg/L [Gejyo et al., 1986; 
Koch, 1992]. 
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This is not expected to be the case for the VFPR, in which the relatively small adsorbent 
particles should allow for a 3-fold decrease in the volume of the adsorbent without a 
significant decrease in efficacy.   
 
Parameter Value Units Parameter Value Units 
0t
APCC
=  0 mg/L Qm 75§ mL/min 
0
,
t
BC iC
=  0 mg/L R 46   
0
,
t
BR iC
=  60* mg/L VBC 52.4 mL 
0t
gelC
=  0 mg/L VBC,i 8.0, 7.5, 7.1, 6.7,  mL 
0t
PLCCC
=  0 mg/L         6.3, 6.0, 5.6, 5.3  
De 1.1 x10-10  m2/s VAPC 175 mL 
HBR 0.31 - Vbed 120 mL 
KD 0.008§ mg/L VBR 7.7** L 
mk  10
-3 m/s VPLCC 20 mL 
NBC 8 - ε 0.4 - 
NBR 3 - Φ 0.87 - 
QBR 200§ mL/min sρ′  2.7 mg/mL 
 
 
                                                 
* Plasma β2m concentrations of chronic hemodialysis patients typically range 20-70 mg/L [Gejyo et al., 1986; 
Koch, 1992]. 
 From Table 3.6. 
 From Table 4.1. 
§ Value determined for yeast-displayed BBM.1 scFv in Chapter 5. 
** This value was chosen so that the blood reservoir would contain 318 mg of β2m at a clinically expected β2m 
concentration.  This blood volume is larger than that which would actually be found in an actual patient (~5 L). 
 From Table 3.4. 
 Value for the hypothetical BBM.1 scFv-based immunoadsorbent described in Section 6.1. 
Table 6.1  Immunoadsorption model input parameters for the large VFPR 
prototype loaded with the hypothetical scFv-based adsorbent. 
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Figure 6.1  Immunoadsorption model-predicted clearance of β2m from whole blood 
by the large VFPR prototype loaded with the hypothetical scFv-based adsorbent. 
Chapter 4 describes the mathematical model in detail, Table 6.1 provides a complete 
listing of the input parameters used, and Chapter 3 describes the large VFPR prototype.   
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6.2  RECOMMENDATIONS FOR FUTURE WORK 
The next milestone for this research project should be the production of 0.1-1.0 L of a 
new scFv-based adsorbent that possesses a β2m-adsorption site density greater than 2 mg-
β2m/mL-settled-gel.  Based on the logic presented in Section 6.1, this is a reasonable goal 
that will require the optimization of the production, purification, and immobilization methods 
for the scFv fragment. 
 
6.2.1  Optimization of ScFv Production 
 A greater than six-fold increase in the secretion level of recombinant glucose oxidase 
by S. cerevisiae has been reported by changing from a shaker flask to a stirred tank batch 
fermentor and optimizing the rates of agitation and aeration [Kapat et al., 1998].  Therefore, 
the effect of varying several culture parameters (mixing pattern, temperature, media 
composition, oxygen level) on the secretion level of BBM.1 scFv (g-scFv/L-culture) by 
YVH10 S. cerevisiae should be studied in a stirred tank batch fermentor.  Furthermore, in 
vitro evolution of the BBM.1 scFv fragment could be performed to increase the expression 
level of the BBM.1 scFv in a yeast display format, which often correlates with secretion 
efficiency [Shusta et al., 1999; Boder and Wittrup, 2000].  The secretion level of the wild-
type BBM.1 scFv fragment without the His6-tag should be studied to determine its effect on 
the secretion efficiency.  This type of purification tag has inhibited the secretion of certain 
scFv fragments by yeast in the Wittrup Laboratory at MIT.*  
It is possible that expressing the BBM.1 scFv fragment as inclusion bodies or as 
soluble active protein in bacteria could be more efficient than the optimized yeast secretion 
system [Datar et al., 1993; Martineau et al., 1998].  Therefore, bacterial expression systems 
for the scFv fragment should also be investigated.  Moving to a bacterial vector would also 
open up the possibility of expressing the scFv as an intein fusion protein, which would offer 
more alternatives for purification and subsequent immobilization through an N-terminal 
cysteine residue or a C-terminal thioester group [Xu and Evans, 2001].   
 
                                                 
* Personal communication with Katarina Midelfort. 
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6.2.2  Optimization of ScFv Purification 
The purification of the His6-tagged scFv fragment by nickel affinity chromatography 
proved to be effective (Chapter 5).  However, the fact that this purification method is 
patented would present a definite drawback if the immunoadsorbent were to be 
commercialized.  Other affinity chromatography ligands that could potentially replace nickel 
include thiol groups and recombinant human β2m.  Activated Thiol Sepharose® 4B is 
commercially available from Amersham Biosciences and recombinant human β2m could be 
immobilized onto Sepharose® CL-4B (following the protocol used to immobilize BBM.1 in 
Section 2.2.2).  Alternatively, recombinant human β2m could be biotinylated (Section 5.2.1) 
and bound to Streptavidin Sepharose® HP (Amersham Biosciences). 
Following the initial purification of the scFv fragment by one of the above affinity 
chromatography methods, one or two additional rounds of chromatographic purification 
should be performed on the scFv fragment before it is used to treat a patient or animal model.  
It is suggested that ion exchange be used to concentrate the scFv fragment followed by size-
exclusion chromatography, which will re-dilute the purified product.  
 
6.2.3  Optimization of ScFv Immobilization 
It is possible that the state of aggregation of the BBM.1 scFv fragment affects its 
amenability for active immobilization.  Therefore, the thermodynamics and kinetics of 
dimerization should be characterized under various buffer conditions (salt concentration, 
scFv concentration, pH, reducing agent concentration).  Size-exclusion chromatography 
could be used to obtain fractions rich in either monomers or dimers and to subsequently 
determine the effect of changes in buffer conditions on the state of aggregation [Pavlinkova 
et al., 1999].  Furthermore, the effect of varying several parameters on the immobilization 
density and molar binding activity for the maleimide-thiol immobilization reaction should be 
studied, including: 
1. The length and hydrophobicity of the spacer arm, either expressed as part of the scFv 
peptide or included in the chemical cross-linking agent. 
2. The reducing conditions of the scFv fragment immediately prior to immobilization.  
Ideally, 100% of the C-terminal free cysteine residues of the scFv fragments should 
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be reduced without reducing the disulfide bridges within the immunoglobulin folds.  
Reducing agents such as immobilized TCEP gel (Section 5.2.5.1), soluble TCEP, 
DTT (dithiothreitol), reduced glutathione, cysteine, or β-mercaptoethanol could be 
used in various amounts and buffers.  Soluble TCEP is reported to have an advantage 
over other types of soluble reducing reagents in that it does not interfere with 
maleimide-thiol reactions [Haugland and Blalgat, 1998].  This reaction should also be 
performed in an oxygen-free environment (degassed buffers in a nitrogen or argon-
filled glove box). 
3. The time, temperature, pH, salt concentration, and reducing agent concentration of 
the maleimide-thiol immobilization reaction. 
4. The scFv concentration and contacting scheme during the immobilization reaction.  
Performing the immobilization reaction at low scFv concentrations could minimize 
spontaneous dimerization (if it is not desired).  Meanwhile, a high scFv concentration 
could increase the conversion of the immobilization reaction.  Therefore, performing 
the immobilization reaction in a plug-flow format with a low concentration of scFv 
could potentially be optimal, as it could minimize dimerization and back-mixing. 
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Appendix:  Immunoadsorption Model FORTRAN 77 
Program 
 
 
        PROGRAM CIRCUIT 
         
C       KM:        MASS-TRANSFER COEFFICIENT [m/sec] 
C       NRSTEP:    NUMBER OF RADIAL STEPS [-] 
C       RADIUS:    AVERAGE BEAD RADIUS [micron] 
C       TTIME:     TOTAL INTEGRATION TIME [minutes] 
C       C0:        INITIAL PATIENT B2M CONCENTRATION [mg/L] 
C       DT:        SCALED TIME STEP [-] 
C       DE:        EFFECTIVE DIFFUSIVITY [m^2/sec] 
C       PA1:       OLD SCALED PATIENT CONCENTRATION 
C       PA2:       NEW SCALED PATIENT CONCENTRATION    
C       KPA:       PATIENT RUNGE-KUTTA PARAMETER 
C       BL0:       INITIAL SCALED BLOOD CHAMBER CONCENTRATION 
C       BL1:       OLD SCALED BLOOD CHAMBER CONCENTRATION 
C       BL2:       NEW SCALED BLOOD CHAMBER CONCENTRATION    
C       KBL:       BLOOD CHAMBER RUNGE-KUTTA PARAMETER 
C       MEM1:      OLD SCALED AVERAGE MEMBRANE CONCENTRATION 
C       MEM2:      NEW SCALED AVERAGE MEMBRANE CONCENTRATION 
C       KMEM:      MEMBRANE RUNGE-KUTTA PARAMETER 
C       PL0:       INITIAL SCALED PLASMA CHAMBER CONCENTRATION 
C       PL1:       OLD SCALED PLASMA CHAMBER CONCENTRATION 
C       PL2:       NEW SCALED PLASMA CHAMBER CONCENTRATION    
C       KPL:       PLASMA CHAMBER RUNGE-KUTTA PARAMETER 
C       BE1:       OLD SCALED BEAD CONCENTRATION  
C       BE2:       NEW SCALED BEAD CONCENTRATION 
C       KBE:       BEAD RUNGE-KUTTA PARAMTER 
C       CC1:       OLD SCALED COLLECTION CHAMBER CONCENTRATION 
C       CC2:       NEW SCALED COLLECTION CHAMBER CONCENTRATION 
C       KCC:       COLLECTION CHAMBER RUNG-KUTTA PARAMETER 
C       VFPR1:     OLD SCALED VFPR EXIT CONCENTRATION 
C       VFPR2:     NEW SCALED VFPR EXIT CONCENTRATION 
C       KVFPR:     VFPR EXIT RUNGE-KUTTA PARAMETER 
C       KD:        ANTIBODY-B2M DISSOCIATION CONSTANT, BASED ON 
C       ===>>>     BULK CONCENTRATION/SETTLED VOLUME  
C       ===>>>>>   [mg-B2m/L-total fluid] 
C       DS:        DENSITY OF B2M BINDING SITES [mg-B2m/settled-L-gel] 
C       PHI:       PARTITION COEFFICIENT [pore conc./surface conc.] 
C       EPS:       GEL BED VOID FRACTION [EMPTY VOL/BED VOL] 
C       SPHI:      GEL BEAD PORE VOLUME FRACTION [L-pores/L-bead] 
C       VPLASMA:   TOTAL PLASMA CHAMBER VOLUME [ml] 
C       VBEAD:     WET GEL BEAD VOLUME [ml] 
C       VBLOOD():  BLOOD CHAMBER VOLUMES (INCL. CELLS) [ml] 
C       VPATIENT:  CELL-FREE PATIENT VOLUME (INCL. CELLS) [ml] 
C       VCC:       VOLUME OF PLAMSA COLLECTION CHAMBER (ml) 
C       Q:         CELL-FREE CIRCUIT FLOWRATE [ml/min] 
C       QM:        PLASMA FLOWRATE THROUGH MEMBRANE [ml/min] 
C       XB:        PLASMA FLOW BYPASS FRACTION [-] 
C       TPROC:     PROCESS TIME SCALE [sec] 
C       TPAT:      PATIENT SPACE-TIME [sec] 
C       TBLOOD():  PLASMA RESIDENCE TIME OF BLOOD COMPARTMENT TANKS [sec] 
C       TPLAS:     PLASMA CHAMBER SPACE-TIME [sec] 
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C       TBEEXT:    BEAD EXTERNAL MASS-TRANSFER TIME SCALE [sec] 
C       TBEINT:    BEAD INTERNAL MASS-TRANSFER TIME SCALE [sec] 
C       ERROR:     RELATIVE ERROR IN MASS BALANCE 
C       TOLER:     MASS BALANCE ERROR TOLERANCE 
C       INBEAD:    TOTAL B2M IN AND ON THE BEADS [mg] 
C       ADSORBED:  TOTAL B2M ADSORBED AT THE END OF SIMULATION 
C       MAXERROR:  THE MAXIMUM AMOUNT OF ERROR IN THE MASS BALANCE 
C       MAXERRJ:   THE TIME STEP NUMBER AT WHICH MAXERROR OCCURS 
C       NPA:       NUMBER OF PATIENT "TANKS-IN-SERIES" 
C       NBL:       NUMBER OF BLOOD COMPARTMENT "TANKS-IN-SERIES" 
C       NPL:       NUMBER OF PLASMA COMPARTMENT "TANKS-IN-SERIES" 
C       PAMASS:    MASS OF B2M IN PATIENT AT TIME T [MG] 
C       BLMASS:    MASS OF B2M IN BLOOD CHAMBER AT TIME T [MG] 
C       PLMASS:    MASS OF B2M IN PLASMA CHAMBER AT TIME T [MG] 
C       MASS0:     INITIAL MASS OF B2M IN THE SYSTEM [MG] 
C       HCT0:      PATIENT HEMATOCRIT 
C       HCT():     BLOOD COMPARTMENT TANK HEMATOCRITS 
C       TOTALVOL:  TOTAL CELL-FREE, POLYMER-FREE, VOLUME OF SYSTEM [L] 
            
        INTEGER I, J, M, NTSTEP, COUNT, NWRITE, MAXERRJ, NPA, NBL, NPL, 
     X           NRSTEP 
 
        REAL*8 RADIUS, C0, KM, DT, KD, DS, PHI, INBEAD, TOLER, ERROR,  
     X      MAXERROR, DR, VPLASMA, VBEAD, VPATIENT,Q, XB, TPROC,  
     X      TPAT, TPLAS, TCC, TBEEXT, BL0, PL0, PAMASS, BLMASS, 
     X   PLMASS, DE, TBEINT, EPS, SPHI, VBLTOTAL, CC1, CC2,  
     X   MEM1, MEM2, VFPR1, VFPR2, KVFPR, KMEM, KCC, HCT0,  
     X   QMUPTOI, MASS0, TOTALVOL 
 
   REAL*8, ALLOCATABLE :: BE1(:,:), BE2(:,:), PA1(:), PA2(:),  
     X    BL1(:), BL2(:), PL1(:), PL2(:), VBLOOD(:), TBLOOD(:), 
     X    KPA(:), KBL(:), KPL(:),KBE(:,:),ADSORBED(:),  
     X       DESORBED(:), HCT(:) 
         
 
C       READ INPUT FILE 
 
        OPEN(UNIT = 5, FILE='INPUT.DAT', STATUS = 'OLD') 
          READ(5,*) BL0, PL0 
          READ(5,*) NPA, NBL, NPL 
          READ(5,*) RADIUS 
          READ(5,*) NRSTEP 
          READ(5,*) TTIME 
          READ(5,*) NWRITE 
          READ(5,*) C0 
          READ(5,*) KM 
          READ(5,*) DE 
          READ(5,*) KD 
          READ(5,*) DS 
          READ(5,*) PHI 
          READ(5,*) SPHI 
          READ(5,*) EPS 
          READ(5,*) VPATIENT 
            VPATIENT = VPATIENT*1000 
 
C       DIMENSION ARRAYS ACCORDINGLY         
          ALLOCATE ( PA1(1:NPA), PA2(1:NPA), BL1(1:NBL), BL2(1:NBL),  
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     X            PL1(1:NPL), PL2(1:NPL), BE1(1:NPL,0:NRSTEP),  
     X            BE2(1:NPL,0:NRSTEP), KPA(1:NPA), KBL(1:NBL),  
     X            KPL(1:NPL), KBE(1:NPL,0:NRSTEP), ADSORBED(1:NPL), 
     X            DESORBED(1:NPL), VBLOOD(1:NBL), HCT(1:NBL),  
     X            TBLOOD(1:NBL) ) 
 
          READ(5,*) HCT0 
          READ(5,*) (VBLOOD(I), I=1,NBL) 
          READ(5,*) VPLASMA 
          READ(5,*) VBEAD 
          READ(5,*) VCC 
          READ(5,*) Q 
          READ(5,*) QM 
          READ(5,*) XB 
          READ(5,*) TOLER 
 
        CLOSE(5) 
 
C       CALCULATE TOTAL BLOOD CHAMBER VOLUME 
        VBLTOTAL = 0 
        DO 5 I= 1,NBL 
           VBLTOTAL = VBLTOTAL + VBLOOD(I) 
  5     CONTINUE 
 
 
C       CALCULATE TIME SCALES 
        TPAT = VPATIENT/Q*60 
        TPLAS = (VPLASMA-(1-EPS)*VBEAD)/((1-XB)*QM)*60 
         
        QMUPTOI = 0 
        DO 7 I = 1, NBL 
           QMUPTOI = QMUPTOI + QM/VBLTOTAL*VBLOOD(I) 
           HCT(I) = Q*HCT0/(Q-QMUPTOI) 
           TBLOOD(I) = 60 * (1-HCT(I))*VBLOOD(I) /  
     X       (QM/VBLTOTAL*VBLOOD(I)+(1-HCT(I))*(Q-QMUPTOI)) 
  7     CONTINUE  
                
        TBEEXT = (RADIUS*1E-6)*(VPLASMA-(1-EPS)*VBEAD)/ 
     X           (3*(1-EPS)*VBEAD*KM*SPHI) 
        TBEINT = (RADIUS*1E-6)**2/DE 
        TCC = VCC/QM*60 
 
 
C       DEFINE THE PROCESS TIME-SCALE 
        TPROC = (VPATIENT+VBLTOTAL*BL0)/(1-XB)/QM*60 
 
                 
C       CALCULATE THE SCALED TIME STEP 
        IF ((TBEINT/(2.2*REAL(NRSTEP)**2)).LT.(TBEEXT*0.05)) THEN 
          DT = TBEINT/TPROC/(2.2*REAL(NRSTEP)**2) 
          PRINT*, 'INTERNAL DIFFUSION LIMITED.' 
        ELSE 
          DT = TBEEXT/TPROC*0.05 
          PRINT*, 'EXTERNAL DIFFUSION LIMITED.' 
        END IF  
 
C       CALCULATE THE SCALED RADIAL STEP 
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        DR = 1/REAL(NRSTEP) 
         
 
C       CALCULATE THE INITIAL MASS OF B2M IN SYSTEM 
        MASS0 = C0/1000 * ( VPATIENT*(1-HCT0) +  
     X                         PL0*(VPLASMA-VBEAD*(1-EPS)) ) 
        TOTALVOL = (VPATIENT*(1-HCT0) + VPLASMA  
     X                       - (1-SPHI)*(1-EPS)*VBEAD + VCC)/1000 
        DO 8 I = 1, NBL 
           MASS0 = MASS0 + C0/1000 * BL0 * VBLOOD(I) * (1-HCT(I))  
           TOTALVOL = TOTALVOL + VBLOOD(I) * (1-HCT(I))/1000 
  8     CONTINUE 
         
 
C       BEGIN WRITING THE PARAMETER OUTPUT FILE 
 
        OPEN(UNIT = 7, FILE='PARAMETER.DAT', STATUS='UNKNOWN') 
          WRITE(7,20) 'INITIAL BLOOD CHAMBER CONCENTRATION:  ', BL0  
          WRITE(7,20) 'INITIAL PLASMA CHAMBER CONCENTRATION:  ', PL0  
          WRITE(7,20) 'PARTICLE RADIUS:  ', RADIUS, ' MICRONS' 
          WRITE(7,25) 'NUMBER OR RADIAL STEPS:  ', NRSTEP 
          WRITE(7,20) 'TOTAL INTEGRATION TIME:  ', TTIME, ' MINUTES' 
          WRITE(7,20) 'INITIAL B2M CONCENTRATION:  ', C0, ' MG/L' 
          WRITE(7,20) 'SCALED TIME STEP:  ', DT 
          WRITE(7,20) 'TIME STEP:  ', DT*TPROC, ' SECONDS' 
          WRITE(7,20) 'MASS-TRANSFER COEFFICIENT:  ', KM, ' M/SEC' 
          WRITE(7,20) 'EFFECTIVE DIFFUSIVITY:  ', DE, ' M^2/SEC' 
          WRITE(7,20) 'BULK DISSOCIATION CONSTANT:  ', KD, ' MG-B2M/L' 
          WRITE(7,20) 'BINDING SITE DENSITY:  ', DS, ' MG-B2M/SETTLED-L' 
          WRITE(7,20) 'PARTITION COEFICIENT:  ', PHI 
          WRITE(7,20) 'PORE VOLUME FRACTION:  ', SPHI,  
     X      ' PORE/BEAD VOLUME' 
          WRITE(7,20) 'SETTLED-BED VOID FRACTION:  ', EPS 
          WRITE(7,20) 'PATIENT VOLUME (CELLS INLC.):  ',  
     X                                       VPATIENT/1000, ' L' 
          DO 10 I = 1, NBL 
             WRITE(7,15) 'BLOOD CHAMBER TANK ',I,  
     X                    ' VOLUME:  ', VBLOOD(I), ' ML' 
  10      CONTINUE    
          WRITE(7,20) 'TOTAL BLOOD CHAMBER VOLUME:  ', VBLTOTAL, 'ML' 
          WRITE(7,20) 'TOTAL PLASMA CHAMBER VOLUME:  ', VPLASMA, ' ML' 
          WRITE(7,20) 'TOTAL BEAD VOLUME:  ', VBEAD, ' ML' 
          WRITE(7,20) 'TOTAL INITIAL CELL-FREE VOLUME: ', TOTALVOL,' L' 
 
          WRITE(7,20) 'INITIAL TOTAL B2M IN SYSTEM:  ', MASS0, ' MG' 
          WRITE(7,20) 'MASS ERROR TOLERANCE:  ', TOLER 
          WRITE(7,20) 'CIRCULATION FLOWRATE (CELL INCL.):  ',  
     X          Q, ' ML/MIN' 
          WRITE(7,20) 'PATIENT HEMATOCRIT:  ', HCT0, ' HCT'  
          DO 11 I = 1, NBL 
            WRITE(7,15) 'BLOOD CHAMBER HCT,', I,': ', HCT(I), 'HCT'        
  11      CONTINUE  
          WRITE(7,20) 'MEMBRANE PLASMA FLOWRATE:  ', QM, ' ML/MIN' 
          WRITE(7,20) 'PLASMA CHAMBER BYPASS FRACTION:  ', XB 
          WRITE(7,20) 'PATIENT SPACE-TIME:  ', TPAT/60, ' MIN' 
          DO 12 I = 1, NBL 
            WRITE(7,15) 'BLOOD CHAMBER TAU,', I,': ', TBLOOD(I), 'SEC'        
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  12      CONTINUE       
          WRITE(7,20) 'PLASMA CHAMBER SPACE-TIME:  ', TPLAS, ' SEC' 
          WRITE(7,20) 'INTERNAL BEAD TIME-SCALE:  ', TBEINT, ' SEC' 
          WRITE(7,20) 'EXTERNAL BEAD TIME-SCALE:  ', TBEEXT, ' SEC' 
          WRITE(7,20) 'PROCESS TIME-SCALE:  ', TPROC/60, ' MIN' 
          WRITE(7,25) 'NUMBER OF PATIENT TANKS:  ', NPA 
          WRITE(7,25) 'NUMBER OF BLOOD CHAMBER TANKS:  ', NBL 
          WRITE(7,25) 'NUMBER OF PLASMA CHAMBER TANKS:  ', NPL 
  15      FORMAT(A19, I1,A10, E12.4, A20) 
  20      FORMAT(A30, E12.4, A20) 
  25      FORMAT(A30, I12, A20) 
 
C       CONVERT KD AND DS FROM A BULK BASIS TO A PORE BASIS 
        KD = KD * PHI 
        DS = DS/SPHI/(1-EPS) 
         
C       SPECIFY INITIAL CONDITIONS         
           
        DO 30 I = 1, NPA 
          PA1(I) = 1.0 
  30    CONTINUE 
        DO 35 I = 1, NBL  
          BL1(I) = BL0 
  35    CONTINUE 
        DO 40 I = 1, NPL 
          PL1(I) = PL0 
          DO 37 M = 0, NRSTEP 
            BE1(I,M) = 0.0 
  37      CONTINUE 
  40    CONTINUE 
 
        CC1 = 0 
        MEM1 = BL0 
        VFPR1 = 1/Q/(1-HCT0) * ( (1-XB)*QM*CC1 + XB*QM*MEM1 +  
     X                          (Q-QM)*BL1(NBL)*(1-HCT(NBL)) ) 
 
C       OPEN PROCESS OUTPUT FILE 
 
        OPEN(UNIT=9, FILE='SYSTEM.OUT', STATUS = 'UNKNOWN') 
        WRITE(9,'(8A14)') 'TIME, MIN','PATIENT','BLOOD', 
     X             'PL CHAMB','LST BD CNTR','PL LINE','INBEAD, MG', 
     X              'ERROR' 
        WRITE(9,'(8E14.5)') 0.0, PA1(NPA), BL1(NBL), PL1(1),  
     X   BE1(NPL,NRSTEP),(XB*MEM1+(1-XB)*CC1), 0.0, 0.0 
 
 
C       INITIALIZE COUNTER AND MAXERROR 
        COUNT = 0 
        MAXERROR = 0.0 
        MAXERRJ = 0 
 
        
C       CALCULATE THE NUMBER OF TIMESTEPS IN THE SIMULATION 
        NTSTEP = INT(TTIME*60/TPROC/DT)+1 
        PRINT*, 'NUMBER OF TIMESTEPS CALCULATED' 
 
C       PERFORM NUMERICAL INTEGRATION USING SECOND ORDER RUNGE-KUTTA 
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        DO 200 J = 1, NTSTEP 
 
C         CALCULATE THE RUNGE-KUTTA PARAMETERS FOR THE PATIENT 
 
          KPA(1) = PA1(1) + REAL(NPA)*0.5*DT*TPROC/TPAT*(VFPR1-PA1(1)) 
          IF (NPA.GT.1) THEN 
            DO 50 I = 2, NPA 
              KPA(I) = PA1(I) +  
     X                 REAL(NPA)*0.5*DT*TPROC/TPAT*(PA1(I-1)-PA1(I)) 
  50        CONTINUE 
          END IF 
           
         
C         CALCULATE THE RUNGE-KUTTA PARAMETERS FOR THE BLOOD CHAMBER 
 
          KBL(1) = BL1(1) +  
     X             0.5*DT*TPROC/TBLOOD(1)*(PA1(NPA)-BL1(1)) 
 
          IF (NBL.GT.1) THEN 
            DO 60 I = 2, NBL         
              KBL(I) = BL1(I) +  
     X                 0.5*DT*TPROC/TBLOOD(I) * (BL1(I-1)-BL1(I)) 
C             PRINT*, 'KBL(', I,') CALCULATED AS: ', KBL(I) 
  60        CONTINUE 
          END IF 
 
 
C         CALCULATE THE RUNGE-KUTTA PARAMETER FOR THE MEMBRANE 
          KMEM = 0 
          DO 62 I = 1, NBL 
            KMEM = KMEM + VBLOOD(I)*KBL(I)/VBLTOTAL          
C            PRINT*, 'KMEM CALCULATED THROUGH TANK ', I, ' AS: ', KMEM 
  62      CONTINUE 
 
 
    
C         CALCULATE THE RUNGE-KUTTA PARAMETERS FOR THE PLASMA CHAMBER 
 
          KPL(1) = PL1(1) +  
     X             REAL(NPL)*0.5*DT*TPROC/TPLAS*(MEM1-PL1(1)) +  
     X             0.5*DT*TPROC/TBEEXT*(BE1(1,0)/PHI-PL1(1)) 
           
          IF (KPL(1).LT.0) THEN 
                PRINT*, 'KPL(1) IS LESS THAN ZERO' 
 
                PRINT*, 'TIME COUNTER (J) = ', J 
                CLOSE (7) 
                CLOSE (9) 
                STOP 
          END IF 
 
C         SPECIFY BEAD SURFACE BOUNDARY CONDITION 
          KBE(1,0) = (KM*PL1(1)+(DE/(DR*RADIUS*1E-6))*BE1(1,1)) /  
     X               (KM/PHI+DE/(DR*RADIUS*1E-6)) 
           
          IF ((J.GT.10).AND.(KBE(1,0).EQ.0)) THEN 
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            PRINT*, 'ERROR:  KBE(1,0) = ', KBE(1,0), ' J = ', J 
            CLOSE(7) 
            CLOSE(9) 
            STOP 
          END IF 
           
          DO 65 M = 1, NRSTEP-1 
            KBE(1,M) = BE1(1,M) + 0.5*TPROC/TBEINT* 
     X                 ((BE1(1,M+1)-2*BE1(1,M)+BE1(1,M-1))*DT/(DR)**2 
     X                 -DT*(BE1(1,M+1)-BE1(1,M-1))/(DR*(1-REAL(M)*DR)))   
 
     X                 / (1+DS*KD/(KD+C0*BE1(1,M))**2) 
  65      CONTINUE 
 
C         SPECIFY NO-FLUX AT THE CENTER 
          KBE(1,NRSTEP) = BE1(1,NRSTEP) + TPROC/TBEINT * 
     X                    (BE1(1,NRSTEP-1)-BE1(1,NRSTEP))*DT/(DR)**2 
     X                    / (1+DS*KD/(KD+C0*BE1(1,NRSTEP))**2)   
 
          IF (NPL.GT.1) THEN 
          DO 70 I = 2, NPL 
            KPL(I) = PL1(I) +  
     X               REAL(NPL)*0.5*DT*TPROC/TPLAS*(PL1(I-1)-PL1(I)) +  
     X               0.5*DT*TPROC/TBEEXT*(BE1(I,0)/PHI-PL1(I)) 
      
C           SPECIFY BEAD SURFACE BOUNDARY CONDITION 
            KBE(I,0) = (KM*PL1(I)+(DE/(DR*RADIUS*1E-6))*BE1(I,1)) /  
     X                 (KM/PHI+DE/(DR*RADIUS*1E-6)) 
 
            DO 67 M = 1, NRSTEP-1 
              KBE(I,M) = BE1(I,M) + 0.5*TPROC/TBEINT* 
     X                   ((BE1(I,M+1)-2*BE1(I,M)+BE1(I,M-1))*DT/(DR)**2 
     X                   -DT*(BE1(I,M+1)-BE1(I,M-1)) /  
     X                   (DR*(1-REAL(M)*DR))) /   
     X                   (1+DS*KD/(KD+C0*BE1(I,M))**2) 
  67        CONTINUE 
 
C           SPECIFY NO-FLUX AT THE CENTER 
            KBE(I,NRSTEP) = BE1(I,NRSTEP) + TPROC/TBEINT * 
     X                      (BE1(I,NRSTEP-1)-BE1(I,NRSTEP))*DT/(DR)**2 
     X                      / (1+DS*KD/(KD+C0*BE1(I,NRSTEP))**2)  
  70      CONTINUE 
          END IF 
          
C         CALCULATE THE RUNGA-KUTTA PARAMETER FOR THE COLLECTION CHAMBER 
AND VFPR 
          KCC = CC1 + 0.5*DT*TPROC/TCC*(PL1(NPL)-CC1) 
          KVFPR = ( (1-XB)*QM*KCC + XB*QM*KMEM +  
     X                      (Q-QM)*KBL(NBL)*(1-HCT(NBL)) ) / Q/(1-HCT0) 
 
C         CALCULATE THE PATIENT CONCENTRATIONS    
 
          PA2(1) = PA1(1) + REAL(NPA)*DT*TPROC/TPAT*(KVFPR-KPA(1))     
          IF (NPA.GT.1) THEN         
          DO 80 I = 2, NPA 
            PA2(I) = PA1(I) + REAL(NPA)*DT*TPROC/TPAT*(KPA(I-1)-KPA(I)) 
  80      CONTINUE 
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          END IF 
 
 
C         CALCULATE THE BLOOD COMPARTMENT CONCENTRATIONS     
 
          BL2(1) = BL1(1) + DT*TPROC/TBLOOD(1) * (KPA(NPA)-KBL(1)) 
          IF (NBL.GT.1) THEN 
          DO 100 I = 2, NBL 
            BL2(I) = BL1(I) +  
     X               DT*TPROC/TBLOOD(I) * (KBL(I-1)-KBL(I)) 
 100      CONTINUE 
          END IF         
           
C         CALCULATE THE NEW MEMBRANE CONCENTRATION 
          MEM2 = 0 
          DO 102 I = 1, NBL 
                MEM2 = MEM2 + VBLOOD(I)*BL2(I)/VBLTOTAL          
 102      CONTINUE         
 
C         CALCULATE THE PLASMA CHAMBER AND BEAD CONCENTRATIONS 
 
          PL2(1) = PL1(1) + REAL(NPL)*DT*TPROC/TPLAS*(KMEM-KPL(1))+  
     X             DT*TPROC/TBEEXT*(KBE(1,0)/PHI-KPL(1)) 
      
         IF (PL2(1).LT.0) THEN 
                PRINT*, 'PL2(1) IS LESS THAN ZERO' 
                PRINT*, 'TIME COUNTER (J) = ', J 
                PRINT*, 'KMEM = ', KMEM 
                PRINT*, 'KPL(1) = ', KPL(1) 
                CLOSE (7) 
                CLOSE (9) 
                STOP 
          END IF 
 
C         SPECIFY BEAD SURFACE BOUNDARY CONDITION      
          BE2(1,0) = (KM*KPL(1)+(DE/(DR*RADIUS*1E-6))*KBE(1,1)) /  
     X                 (KM/PHI+DE/(DR*RADIUS*1E-6)) 
           
          IF ((J.GT.10).AND.(BE2(1,0).EQ.0)) THEN 
            PRINT*, 'ERROR:  BE2(1,0) = ', BE2(1,0), ' J = ', J 
            CLOSE(7) 
            CLOSE(9) 
            STOP 
          END IF 
           
          DO 105 M = 1, NRSTEP-1 
            BE2(1,M) = BE1(1,M) + TPROC/TBEINT* 
     X                 ((KBE(1,M+1)-2*KBE(1,M)+KBE(1,M-1))*DT/(DR)**2 
     X                 -DT*(KBE(1,M+1)-KBE(1,M-1))/(DR*(1-REAL(M)*DR)))   
     X                 / (1+DS*KD/(KD+C0*KBE(1,M))**2) 
 105      CONTINUE 
 
C         SPECIFY NO-FLUX AT THE CENTER 
          BE2(1,NRSTEP) = KBE(1,NRSTEP) + TPROC/TBEINT * 2 * 
     X                    (KBE(1,NRSTEP-1)-KBE(1,NRSTEP))*DT/(DR)**2 
     X                    / (1+DS*KD/(KD+C0*KBE(1,NRSTEP))**2)   
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          IF (NPL.GT.1) THEN 
           
            DO 110 I = 2, NPL 
              PL2(I) = PL1(I) +  
     X                 REAL(NPL)*DT*TPROC/TPLAS*(KPL(I-1)-KPL(I)) +  
     X                 DT*TPROC/TBEEXT*(KBE(I,0)/PHI-KPL(I)) 
 
C             SPECIFY BEAD SURFACE BOUNDARY CONDITION 
              BE2(I,0) = (KM*KPL(I)+(DE/(DR*RADIUS*1E-6))*KBE(I,1))/  
     X                   (KM/PHI+DE/(DR*RADIUS*1E-6)) 
                
              DO 107 M = 1, NRSTEP-1 
                BE2(I,M) = BE1(I,M) + TPROC/TBEINT* 
     X                     ((KBE(I,M+1)-2*KBE(I,M)+KBE(I,M-1)) *  
     X                     DT/(DR)**2-DT*(KBE(I,M+1)-KBE(I,M-1)) /  
     X                     (DR*(1-REAL(M)*DR))) /  
     X                     (1+DS*KD/(KD+C0*KBE(I,M))**2) 
  107         CONTINUE 
C             SPECIFY NO-FLUX AT THE CENTER 
              BE2(I,NRSTEP) = KBE(I,NRSTEP) + TPROC/TBEINT * 
     X                        (KBE(I,NRSTEP-1)-KBE(I,NRSTEP))*DT/(DR)**2 
     X                        / (1+DS*KD/(KD+C0*KBE(I,NRSTEP))**2)  
      
 110      CONTINUE          
          END IF 
        
C       CALCULATE THE COLLECTION CHAMBER AND VFPR CONCENTRATIONS 
          CC2 = CC1 + DT*TPROC/TCC*(KPL(NPL)-KCC) 
          VFPR2 = ( (1-XB)*QM*CC2 + XB*QM*MEM2 + (Q-QM)*BL2(NBL)*  
     X                (1-HCT(NBL)) ) / Q / (1-HCT0) 
 
               
C       RESET CONCENTRATION VARIABLES AND CALCULATE COMPARTMENT MASSES 
 
        PAMASS = 0.0 
        BLMASS = 0.0 
        PLMASS = 0.0 
        INBEAD = 0.0 
       
        DO 120 I = 1, NPA 
          PA1(I) = PA2(I) 
          PAMASS = PAMASS + PA1(I)*VPATIENT*(1-HCT0)*C0/1000/REAL(NPA) 
 120    CONTINUE 
 
  
        DO 130 I = 1, NBL 
          BL1(I) = BL2(I) 
          BLMASS = BLMASS + BL1(I)*VBLOOD(I)*(1-HCT(I))*C0/1000 
 130    CONTINUE 
 
        DO 140 I = 1, NPL 
          PL1(I) = PL2(I) 
          PLMASS = PLMASS +  
     X             PL1(I)*(VPLASMA-(1-EPS)*VBEAD)*C0/1000/REAL(NPL) 
               
          BE1(I,NRSTEP) = BE2(I,NRSTEP) 
          ADSORBED(I) = 0.0 
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          DESORBED(I) = 0.0 
          DO 135 M = 0, NRSTEP-1 
            BE1(I,M) = BE2(I,M) 
            ADSORBED(I) = 3*VBEAD*(1-EPS)/1000*DR*C0*(DS*(BE1(I,M) +  
     X                    BE1(I,M+1))/2 
     X                    /(KD+C0*(BE1(I,M)+BE1(I,M+1))/2))/REAL(NPL)  
     X                    * (1-(M+0.5)*DR)**2 * SPHI + ADSORBED(I)  
            DESORBED(I) = 3*VBEAD*(1-EPS)/1000*DR*C0 *  
     X                    (SPHI*(BE1(I,M)+BE1(I,M+1))/2) 
     X                    / REAL(NPL) * (1-(M+0.5)*DR)**2 + DESORBED(I) 
 135      CONTINUE 
         
          INBEAD = INBEAD + ADSORBED(I) + DESORBED(I) 
             
 140    CONTINUE 
 
        MEM1 = MEM2 
        CC1 = CC2 
        VFPR1 = VFPR2 
 
C       CONFIRM THE B2M MASS BALANCE 
      
        ERROR = 1 - ( PAMASS + BLMASS + PLMASS + INBEAD +  
     X                                          C0*VCC*CC1/1000 )/MASS0 
 
         
        IF ((ABS(ERROR)).GT.(ABS(MAXERROR))) THEN 
          MAXERROR = ERROR 
          MAXERRJ = J 
        END IF 
 
 
C       WRITE THE CONCENTRATION PROFILE TO THE OUTPUT FILES         
 
        IF (INT((DBLE(NTSTEP)/DBLE(NWRITE))).EQ. 
     X     (INT(DBLE(J)-DBLE(COUNT) *  
     X     DBLE(NTSTEP)/DBLE(NWRITE)))) 
     X  THEN 
          WRITE(9,'(8E14.5)') REAL(J)*DT*TPROC/60,  
     X      PA1(NPA), BL1(NBL), PL1(NPL), BE1(NPL,NRSTEP), 
     X      ((1-XB)*CC1+XB*MEM1),  
     X      INBEAD, ERROR      
 
 145      FORMAT(A35,E14.5)          
          COUNT = COUNT + 1 
        END IF 
 
C       WRITE MASS BALANCE ERROR MESSAGE AND QUIT 
 
        IF (ABS(ERROR).GT.(TOLER)) THEN 
          PRINT*, 'ERROR:  B2M MASS BALANCE VIOLOATION.' 
 
          WRITE(9, *) 'ERROR: B2M MASS BALANCE VIOLOATION.' 
          WRITE(9, *) 'J =  ', J, ' (NUMBER OF TIME STEPS)' 
          WRITE(9, *) 'PERCENT ERROR:  ', ERROR*100 
          CLOSE(7) 
          CLOSE(9) 
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          STOP 
        END IF 
         
 
  200   CONTINUE         
         
 
C       FINISH WRITTING THE PARAMTER OUTPUT FILE        
 
        WRITE(7,*) 
        WRITE(7,20) 'TOTAL B2M IN THE BEADS:  ', INBEAD, 'MG'   
        WRITE(7,20) 'MAXIMUM MASS BALANCE ERROR:  ',MAXERROR*100, 
     X               'PERCENT' 
        WRITE(7,25) 'TIME STEP NO. AT MAXERROR:  ',MAXERRJ, ' ' 
        WRITE(7,20) 'TIME AT MAX ERROR:  ',  
     X    MAXERRJ*DT*TPROC/60, ' MIN'  
        WRITE(7,20) 'FINAL TOTAL SYSTEM B2M:  ', PAMASS + BLMASS +  
     X                        PLMASS + INBEAD + C0*VCC*CC1/1000, ' MG'               
        WRITE(7,20) 'FINAL MASS BALANCE ERROR:  ', ERROR*100,'PERCENT' 
        WRITE(7,20) 'FINAL MEAN PATIENT CONCENTRATION:  ', 
     X       PAMASS/(1-HCT0)/VPATIENT*1000, 'MG/L' 
        WRITE(7,20) 'FINAL MEAN PLASMA CHAMBER CONC.:  ', 
     X       PLMASS/(1-EPS)/VPLASMA*1000,'MG/L' 
        WRITE(7,20) 'FINAL PLASMA LINE CONC.:  ',  
     X      (XB*MEM1+(1-XB)*CC1)*C0, 'MG/L' 
        WRITE(7,20) 'FINAL BEAD CENTER CONC.S (MG/L):  ' 
        WRITE(7,300) (C0*BE1(I,NRSTEP), I=1,NPL)  
 300    FORMAT(10E14.5)         
 
 
C       CLOSE OUTPUT FILES 
        CLOSE(7) 
        CLOSE(9) 
         
        END 
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